Document:

Exhibit
10.1

 

CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED
AND REPLACED WITH “ [***]” BECAUSE IT IS  NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT PETVIVO HOLDINGS, INC. TREATS
AS PRIVATE OR CONFIDENTIAL.

 

DISTRIBUTION
SERVICES AGREEMENT

 

This
Distribution Services Agreement (“Agreement”) is made as of June 17, 2022 (“Effective Date”), by
and between MWI Veterinary Supply Co., an Idaho corporation (“MWI”), and PetVivo, Inc. (“Supplier”).
Intending to be legally bound, the parties hereby agree as follows:

 

1.
SERVICES.

 

1.1
Appointment. Supplier hereby authorizes and appoints MWI to distribute, advertise, promote, market, supply, and sell (collectively,
“Distribution” or “Distribution Services”) the Products within the United States of America (the
“Territory”) and agrees to sell the Products to MWI as ordered by MWI from time to time in MWI’s sole discretion.
This authorization and appointment shall designate MWI as the exclusive veterinary product distributor of Products for a period of two
years commencing upon the execution of this Agreement and shall transition to a non-exclusive veterinary product distributor designation
for all subsequent years of the Term thereafter; provided that, Supplier shall extend such exclusivity for a third year upon MWI achieving
the mutually agreed [***] target for the second year. The term “Products” means all animal health and related products
of Supplier that are identified in the Pricing Schedule of Exhibit A and are purchased by MWI. Supplier shall make available for purchase
by MWI all products Supplier makes available for purchase to any other animal health distributors or resellers of similar or smaller
size (“Comparable Distributors”).

 

1.2
Contract Price. Supplier shall sell the Products to MWI at a price (“Contract Price”) equal to the lower of
(a) the price listed in the Pricing Schedule which is attached hereto as Exhibit A (as adjusted in accordance with Section 1.4), or (b)
the lowest price Supplier sells to any other Comparable Distributors. In addition, Supplier will provide MWI the incentives described
in Exhibit A. MWI is solely responsible for determining the price and other terms at which MWI sells the Products to its customers.

 

1.3
Net Price Requirement. Notwithstanding any other provision of this Agreement, Supplier shall ensure the Contract Price is at all
times equal to or lower than the lowest Net Price at which Supplier sells any relevant Product to any other Comparable Distributors by
immediately providing MWI the same incentives, discounts, rebates, bonuses, commissions and/or promotions provided to other Comparable
Distributors or adjusting the Contract Price as necessary or, failing that, issuing a credit on the next applicable invoice. “Net
Price” means the net purchase price for a Product after application of all applicable incentives, discounts, rebates, bonuses,
commissions, and promotions, (including national, regional and local sales, rebate, and other promotional programs), whether temporary
or permanent, but excluding any early pay discounts.

 

1.4
Price Changes. Subject to Sections 1.3 and 1.5 and with 30 days’ prior written notice to MWI, Supplier may prospectively
increase the Contract Price for any Product but only by a percentage that is equal to or less than the percentage increase applied to
all other Comparable Distributors. The removal or reduction in any incentives, discounts, rebates, bonuses, commissions, or promotions
offered to MWI are considered price increases subject to the requirements of this Section 1.4. In the event of any price increase, MWI
shall be entitled to purchase Product (based on the training 12 month purchase history or, if shorter, the period of time that MWI has
purchased such Product from Supplier) at the [***] price for the entire notice period. Supplier may decrease the Contract Price at any
time upon written notice; provided however, Supplier will provide [***] by paying MWI in an amount equal to [***].

 

    	Distribution Services Agreement – Page 1

    	 

    

 

1.5
List Price. In the event that Supplier unilaterally establishes, or has established, for any Product a list price, vet list price,
manufacturer’s suggested retail price, or suggested veterinary price (collectively, “List Price”), Supplier
(a) may only increase the Contract Price in connection with an increase in the List Price and any increase to the Contract Price may
not exceed the simultaneous percent increase in the List Price, and (b) shall immediately decrease the Contract Price in proportion to
any decrease to the List Price, in each case as necessary to ensure that the percent difference between the List Price and the Contract
Price does not decrease.

 

1.6
Chargebacks & Reimbursements.

 

(a)
If Supplier agrees with any customer (excluding other distributors) to have any Product supplied at a specific or discounted price (“Customer
Price”) or removes or modifies any Customer Price, Supplier will promptly notify MWI of such Customer Price. For each Product
MWI sells to a customer with Customer Pricing, Supplier will issue MWI a chargeback equal to [***]. The chargeback is exclusive of any
service fees, incentives, or other reimbursements payable to MWI under this Agreement.

 

(b)
In the event Supplier extends or makes available any promotion, incentive or special offer or program to any customer of MWI (including
extended payment terms, temporary discounts, free goods with a purchase, new practice offers, and the like), Supplier will allow MWI
to match the terms of such offer and [***]. [***] for extended payment terms will be calculated at a rate of [***] for each day of extended
payment terms beyond 30 days.

 

(c)
Supplier will [***] in connection with MWI’s Distribution of Products to such retailer.

 

(d)
All chargebacks and reimbursements payable pursuant to this Section 1.6 are due on the 10th day of the month following the sale of the
Product.

 

1.7
Primary Distribution Services. For the primary Distribution Services performed by MWI, which may include stocking, packing, and
shipping Products; inventory management; customer validation and monitoring; order management; inventory and sales data collection and
management; receivable risk management; and category management, Supplier shall pay MWI an amount equal to [***] times the monthly gross
purchases of Products calculated at the Contract Price (“Distribution Services Fee”), which includes a [***]. The
Distribution Services Fee shall be invoiced monthly and payment shall be due within 15 days of the date of the invoice and is subject
to MWI’s right to setoff. The Distribution Services Fee is a bona fide fee for service negotiated at arm’s length and together
with any other services fees set forth herein, shall at all times be equal to or higher than any services fees paid to any other Comparable
Distributor.

 

1.8
Standard Terms and Conditions; Continuing Guaranty. The sale, purchase, and Distribution of Products and all respective rights
and obligations of the parties under this Agreement shall be governed by the DSA Standard Terms and Conditions set forth in Exhibit B.
Supplier accepts and agrees to the terms of, and shall execute and deliver contemporaneously with this Agreement, the Continuing Guaranty
and Indemnification Agreement (the “Continuing Guaranty”) set forth as Schedule A.

 

    	Distribution Services Agreement – Page 2

    	 

    

 

2.
PRODUCTS.

 

2.1
Ordering. MWI will submit orders to Supplier via Electronic Data Interchanges (“EDIs”) in an industry-standard
format or other format reasonably acceptable to both parties. Supplier will, within 2 business days of order placement, confirm acceptance
or rejection of MWI’s order and confirm the Product quantity, shipping date, delivery location and Contract Price, in an acceptable
electronic format. Supplier shall not unreasonably reject any order from MWI. Supplier will accept orders at the Contract Prices in effect
on the day the order is transmitted. No order will be canceled after acceptance by Supplier without MWI’s prior written approval.

 

2.2
Shipping; Risk of Loss; Title. Supplier shall, within 7 calendar days of Supplier’s confirmation of MWI’s order or
such later date as MWI may request, ship the Products DDP – Delivered Duty Paid (Incoterms 2010) directly to the distribution center
or other location designated by MWI. Supplier shall pay all costs associated with delivering the Product to MWI, including freight, detention,
demurrage, sorting, packing, and segregation, except to the extent any such charges result from MWI’s failure to timely accept
any proper shipment of conforming Products. Supplier will not ship any partial cases of Products to MWI. Title and risk of loss for the
Products shall pass from Supplier to MWI upon MWI’s receipt of delivery of such Products in good order and condition at MWI’s
distribution center or other destination designated by MWI.

 

2.3
Payment for Products. Supplier will invoice MWI when Products are shipped to MWI. All invoices shall be submitted electronically
in an industry standard format or other format mutually acceptable to the Parties. MWI may, at MWI’s option, pay Supplier by Automated
Clearing House (ACH) or wire transfer to an account designated in writing by Supplier, check, or credit card. MWI will pay all Supplier
invoices for undisputed orders on terms of: net 60 days from date Products are delivered to MWI.

 

2.4
Product Capacity. Supplier will maintain capacity to supply Products historically purchased by MWI at all times during the Term
of this Agreement, in the amount no less than of [***] of MWI’s [***] of that Product (based on the [***]). Within 90 days following
the six month anniversary of the Effective Date of this Agreement, the Parties will reassess whether the Supplier’s monthly capacity
requirement of [***] should be increased or decreased and if the Parties agree to such a change, will negotiate in good faith a new Supplier’s
monthly capacity. [***].

 

2.5
Shortages. In the event that Supplier anticipates that it will not be able to maintain the capacity requirements set forth in
Section 2.4, Supplier shall notify MWI within 48 hours and the parties shall promptly meet to discuss the potential shortage. Supplier
shall provide a written plan of action stating in reasonable detail the identifiable cause and proposed measures to remedy the potential
shortage and the date such shortage is expected to end. [***]. Such allocations shall continue until Supplier no longer anticipates the
potential shortage set forth in Section 2.4.

 

    	Distribution Services Agreement – Page 3

    	 

    

 

2.6
Short Dated Product. For Products with an expiration date, Supplier will not ship any Products with less than 18 months’
shelf life remaining (“Short Dated Product”), unless (a) the Product is manufactured with a limited shelf life less
than the above, in which case (i) Supplier will notify MWI of such shorter shelf life at the time of order acceptance, (ii) such Product
will be shipped per Supplier’s guidelines if MWI elects to proceed with the order, and (iii) such Product will have a minimum of
80% of its total shelf life remaining at the time of shipment to MWI, or (b) MWI, in its sole discretion, accepts such shipment of Short
Dated Product in writing on a case-by-case basis in individual purchase situations.

 

2.7
New Product Launches. For Products new to market, MWI and Supplier will jointly determine the amount of Products to be included
in the initial stocking order and an appropriate evaluation period, which will be no less than 8 months from the date the initial stocking
order is delivered to MWI. Beginning 6 months after the delivery of the initial stocking order and continuing until the end of the agreed-upon
evaluation period, [***]. Supplier will grant MWI extended payment terms of net 3 months and invoice MWI separately for all new Products
ordered during the evaluation period. Supplier will provide MWI with complete new item set up material for all new Products, including
HDA Product Specification Form, label reproduction, layout or facsimile, dimensions and Safety Data Sheet (SDS) prior to shipping such
Product.

 

2.8
Free Goods. Upon Supplier’s request, MWI may agree to distribute free, promotional or no-cost Products, including samples
and replacement products (collectively, “Free Goods”), in MWI’s sole discretion. In the event MWI distributes
any Free Goods pursuant to Supplier’s request, Supplier agrees to issue a reimbursement to MWI for (a) any and all amounts paid
or payable by MWI for the Free Goods, and (b) any mutually agreed upon logistics fee or other compensation. The reimbursement for Free
Goods shall be due within 30 days of the date of Supplier’s receipt of MWI’s report of monthly Sales Data and the shipment
details of all distributed Products and is subject to MWI’s right to setoff. [***].

 

3.
TERM; TERMINATION.

 

3.1
Term. This Agreement is effective as of the Effective Date and will continue in effect for a period of 1 year (as renewed or extended,
the “Term”). Thereafter, the Term will automatically renew for subsequent terms of 12 months unless either party elects
not to renew the Term by providing written notice to the other party at least 60 days’ prior to the end of the then current Term.

 

3.2
Termination. Either party may terminate this Agreement for cause (a) upon 30 days’ written notice of a material default
to the other party and failure of that party to cure the default within the 30 day period or (b) immediately upon the other party’s
insolvency, voluntary or involuntary bankruptcy, suspension of business, assignment of assets for the benefit of creditors, voluntary
dissolution, or appointment of a trustee or receiver for all or a substantial portion of the other party’s assets.

 

    	Distribution Services Agreement – Page 4

    	 

    

 

4.
RETURNS.

 

4.1 Unopened
Products. MWI will request a return authorization from Supplier and Supplier shall issue such authorization within 15 days of
MWI’s request. If Supplier does not respond to MWI’s return authorization request within 30 days, MWI will process the
Product return and either invoice or deduct the refund from Supplier invoice. Except for Products documented to have been purchased
on a non-returnable basis, MWI may return unopened Products to Supplier at any time up to [***] days prior to the expiration date of
the Product for a full refund. Notwithstanding the previous sentence, all unopened Products returned to MWI by a MWI customer may be
returned to Supplier at any time up to [***] days past the expiration date of the Product for a [***] refund. [***] will be
responsible for return shipping costs for all returned Products that are not shipment errors, damaged, or otherwise defective or
non-conforming. No [***] fees will apply. Title and risk of loss for returned Products will pass from MWI to Supplier upon delivery
of the Products to Supplier. Upon receipt of the return, Supplier shall credit MWI at the then current [***] within 30
days.

 

4.2
Nonconforming Products. Supplier will issue a full refund at the then current [***] and pay for all return shipping costs for
any Product that (a) does not conform to the Limited Warranties (defined in Exhibit B, Section 4) or any specific requirement of this
Agreement, (b) has been recalled by Supplier or any governing agency, or (c) is a Short Dated Product that was not preapproved by MWI.

 

4.3
Shipment Errors. Supplier shall immediately contact the MWI purchasing department regarding any delay or failure of delivery,
incomplete shipment, leakage or spillage during shipment, shortage in shipment, misdirection of any delivery, or over shipment and shall
comply with any reasonable directions provided by MWI. MWI shall have the right to cancel any such order without penalty and Supplier
will be responsible for any related freight or accessorial charges and other costs and expenses caused by the error.

 

4.4
Damaged Products. Should MWI receive any Products in apparent damaged condition, MWI will note on the delivery slip the apparent
damage and promptly notify Supplier. MWI will report any concealed damage or latent defects within 30 days of discovery. Supplier will
credit MWI for such damaged Products at the invoice price within 30 days of MWI’s notification. MWI will hold such damaged Products
for inspection by the insurer, the carrier, or Supplier’s designated representative for up to 30 days.

 

4.5
[***] of Remaining Inventory. MWI may return, for a [***]at the then current Contract Price, any unopened Products still
in MWI’s possession (“Remaining Inventory”) upon or after the expiration or termination of this Agreement. If
MWI does not return all of the Remaining Inventory (a) MWI may sell such Remaining Inventory and will remain an authorized distributor
of the Products and (b) this Agreement shall remain in effect with respect to the Distribution of such Remaining Inventory, in each case
for the limited purpose of MWI selling the Remaining Inventory until all of the Remaining Inventory is sold.

 

4.6
Supplier’s Return Policy. Subject to the terms of this Section 4, MWI will use commercially reasonable efforts to follow
the reasonable procedural requirements set forth in any Supplier Returned Goods Policy (“SRGP”) attached to this Agreement
as an Exhibit. Supplier must propose any changes to its SRGP by providing MWI with at least 30 days’ prior written notice and MWI
may reject any such proposed changes by notifying Supplier within 60 days of receipt of Supplier’s proposal. In the event of a
conflict between any SRGP and this Agreement, this Agreement controls.

 

    	Distribution Services Agreement – Page 5

    	 

    

 

5.
MISCELLANEOUS.

 

5.1
No Minimum Requirements. Nothing in this Agreement will be interpreted to require or obligate MWI to (a) purchase or pay for any
minimum amount of Products, (b) purchase any portion of its requirements for the Products from Supplier, or (c) comply with any quota,
sales targets, sales minimum, or other sales objectives. Statements by MWI regarding present or future markets, conditions, expectations,
orders, estimates, forecasts, outlooks, objectives, plans, goals, intentions and other words or phrases of similar import are only beliefs
about the present and future and do not constitute any obligation or binding commitment of MWI.

 

5.2
Established Accounts. Supplier may directly sell Products within the Territory to designated and currently established accounts
(“Established Accounts”) without liability (including but not limited to any monetary obligation) to Distributor or otherwise
breaching the terms of this Agreement. Established Accounts means: (a) parties who have purchased Products from Supplier prior to the
Effective Date of this Agreement, (b) parties who require that they deal directly with the Supplier, (c) governmental agencies, and (d)
parties that order via the internet who are not directly solicited by the Supplier to purchase the Products.

 

5.3
Notices. Any notice required or permitted hereunder will be in writing and will be deemed given upon delivery, when delivered
personally or by overnight courier, or email with confirmation of receipt, or the third business day after being deposited in the U.S.
mail as registered or certified mail, postage prepaid, return receipt requested, addressed to the receiving party at its address indicated
below its signature to this Agreement or to such other address as such party has indicated by written notice.

 

5.4
Entire Agreement. The Exhibits identified in this Agreement are incorporated herein by reference and made a part hereof as if
set out in full herein. Except for any Continuing Guaranty, this Agreement constitutes the entire agreement and understanding of the
parties and supersedes any prior agreements and understandings between the parties with respect to the specific subject matter hereof.
In the event of any conflict between this Agreement and its Exhibits, this Agreement shall control; in the event of any conflict between
this Agreement and the Continuing Guaranty, the Continuing Guaranty shall control. For purposes of clarity, the terms and conditions
of a purchase and sale of Products shall be controlled only by this Agreement (including its Exhibits) and shall not be varied or supplemented
by the terms of purchase or sale otherwise used by Supplier or MWI or set forth on any purchase order, acknowledgement, or other documents
relating to an order. This Agreement shall not supersede any agreements in place between the parties related to MWI private label products
manufactured by Supplier for MWI.

 

5.5
Modifications; Waivers. This Agreement may not be altered, amended or changed in any way except by a written instrument executed
by both parties. No waiver of any rights or obligations shall be (a) implied, whether by course of dealing, any failure or delay in exercising
any right, power or privilege hereunder, or otherwise, or (b) effective unless in writing and signed by the party holding such rights
or to whom such obligations are owed. Any waiver shall be effective only in the specific instance and for the specific purpose stated
in such writing and shall not obligate the waiving patty to grant any further or similar waivers.

 

5.6
Survival. All rights, obligations or liabilities accrued hereunder prior to the expiration or termination of this Agreement and
all provisions under this Agreement, which, by their terms and conditions, show the parties intended them to survive the expiration or
termination of this Agreement, including provisions governing confidentiality, indemnification, warranties, returns, recalls, insurance
and liability, will survive the expiration or termination of this Agreement. The Continuing Guaranty is an independent agreement that
supplements this Agreement and will survive the expiration or termination of this Agreement. Notwithstanding any expiration or termination
of this Agreement, the terms and conditions of this Agreement shall survive and continue to apply to any purchase or Distribution of
Products by MWI until the parties have entered into a written agreement that replaces this Agreement.

 

5.7
Counterparts; Originals. This Agreement may be executed and delivered in counterparts and by facsimile, PDF or other electronic
format, each of which will be deemed an original but all of which will constitute one and the same instrument.

 

[Signatures
on Following Page]

 

    	Distribution Services Agreement – Page 6

    	 

    

 

IN
WITNESS WHEREOF, the parties by their authorized representatives have executed this Agreement as of the date first set forth above.

 

	SUPPLIER: PetVivo,
    Inc.	 	MWI
    VETERINARY SUPPLY CO.
	 	 	 
	Signature:	/s/
    John Lai	 	Signature:	/s/
    Steve Shell
	Name:	John
    Lai	 	Name:	Steve
    Shell
	Title:	Chief
    Executive Officer	 	Title:	President,
    MWI Animal Health

 

	Address
    for Notices:

    5151
    Edina Industrial Blvd.

    Suite
    575

    Edina,
    MN 55439

    Email:
    mmiddleton@petvivo.com

    Attn:
    Mark Middleton, National Sales Director

    With
    a Copy to same address:

    Email:
    jdolan@petvivo.com

    Attn:
    Legal Department
	 	Address
    for Notices:

    MWI
    Veterinary Supply Co.

    3041
    W. Pasadena Dr.

    Boise,
    ID 83705

    Email:
    CategoryManagement@mwianimalhealth.com

    Attn:
    Vice President, Animal Health Sourcing

    With
    a Copy to same address:

    Email:
    Legal@mwiah.com

    Attn:
    Legal Department

 

    	Distribution Services Agreement – Page 7

    	 

    

 

Exhibit
A

 

PRICING
SCHEDULE

 

Contract
Price List:

 

	Product	 	 	Size/Quantity	 	 	Contract Price	 	 	List Price	 
	Spryng - (sold in cases of 6 syringes each)	 	 	[***]	 	 	$[***] ($*** for a case of 6 syringes)	 		$***	 

 

Incentives:

 

Performance
Rebate:

 

a.
Within 2 months after each anniversary of the Effective Date, Supplier shall pay to MWI an annual performance rebate (“Performance
Rebate”) on the aggregate purchase price of all Products purchased by MWI in such year. The applicable rate for the first year
is set forth in the table below if MWI’s purchases for such year meet the minimum number of syringes identified in the Annual Purchase
Target of the table below. For each subsequent term of 12 months, the Parties shall negotiate in good faith a new Annual Purchase Target
that must be achieved for MWI to obtain a Performance Rebate incentive for each respective 12 month period.

 

b.
Supplier shall pay the Performance Rebate within 45 days after the end of each calendar year in which MWI earns such Performance Rebate.

 

	Annual
    Performance Target	 	Performance
    Rebate	 
	[***]	 	[***]%	 
	[***]	 	Additional
    [***]%	 
	[***]	 	Additional[***]%	 

 

    	Distribution Services Agreement – Exhibit A

    	 

    

 

Exhibit
B

 

DSA
STANDARD TERMS AND CONDITIONS

 

Purchase
of Products and Distribution Services

 

1.
Supplier’s Responsibilities.

 

1.1
License Grant. For the Term of this Agreement and any extension thereafter, Supplier hereby grants MWI a non-exclusive, perpetual,
royalty-free, sublicensable (to MWI’s customers that purchase Products from MWI) license to use Supplier’s Product images,
trademarks, service marks, logos, trade dress, and other distinctive brand features solely in connection with the Distribution and resale
of the Products in the Territory.

 

1.2
Promotional Materials; Advertising. Supplier shall supply MWI, at Supplier’s cost, catalogs, circulars and other promotional
and informational material regarding the Products as mutually agreed. Supplier will ensure that all such material and any other marketing
or promotional materials or language provided to MWI is (a) accurate, truthful and not false or misleading; (b) supported by appropriate
scientific and/or medical research; (c) fairly balanced in its discussion of risks and benefits of Products; (d) consistent with and
supported by FDA approved prescribing information or instructions for use, as applicable; (e) in compliance with all applicable FDA regulations
pertaining to the promotion of the Products and Applicable Laws; and (f) subject to a reasonable expiration date. MWI may alter such
materials or develop other materials in connection with the Distribution of Products (including product brochures and sales aids), subject
to Supplier’s review and prior written approval, and Supplier is solely responsible to confirm that all such materials satisfy
and comply with all legal requirements, including applicable FDA regulations. MWI may freely use information related to Products made
publicly available by Supplier. Supplier will also support MWI through Supplier’s active promotion of the Products by advertising
and other promotional activities as mutually agreed by Supplier and MWI.

 

1.3
Training. Supplier shall supply, at Supplier’s cost and by Supplier representatives, (a) educational and training programs
for MWI’s personnel and (b) wet lab, clinical, educational, and training programs for MWI’s customers and other end-users
of the Products, all at such times and locations as mutually agreed.

 

1.4
Packaging. Supplier shall clearly label all cartons and pallets with the following shipping information: (a) MWI Purchase Order
Number, (b) Ship-From Address, (c) Ship-To Address, (d) Product Description (not applicable for controlled substances), (e) Item Number,
and (f) Case Quantity. For all cartons and pallets containing controlled substances, in addition to the foregoing labeling requirements,
Supplier shall (i) label such packaging with DEA numbers and the symbol designating the schedule in which such controlled substance is
listed, in a prominent location and in a font that is clear and large enough to afford prompt identification, (ii) securely seal such
packaging so as to disclose any tampering or opening of such packaging, in each case as set forth in 21 U.S.C. 821, 825, 871(b), 958(e)
(Labeling and Packaging Requirements for Controlled Substances), and (iii) adhere to all other Applicable Laws regarding the packaging
of such controlled substances. Supplier shall label, package and transport the Products to MWI in accordance with all applicable federal,
state, local, foreign and other laws, rules and regulations (“Applicable Laws”) and in a manner that reasonably protects
against breakage, leakage, contamination or spillage. Each container holding liquid Products shall be liquid tight and have a liquid
tight seal in addition to a fully fastened liquid tight cap. Any squirt handles, sprayers, pumps or similar fixtures shall be included
separately with, and not installed in, such containers. Supplier will be responsible for any damage, including damage caused to other
products, equipment or property, caused by any Product leaks resulting from Supplier’s failure to comply with the requirements
of this Section.

 

    	Distribution Services Agreement – Exhibit B

    	 

    

 

1.5
Compliance with Laws. Supplier shall comply with all Applicable Laws, including (a) those governing the manufacture, purchase,
handling, sale, marketing, labeling, packaging, storage, shipping, and distribution of Products, including the labeling requirements
set forth in the California Safe Drinking Water and Toxic Enforcement Act of 1986 (Cal. H.S.C. §§ 25249.5-25249.13), (b) requirements
that Supplier publicly identify its authorized distributors, and (c) government contractual requirements. Supplier understands that MWI
sells, or may sell, products (including the Products) to governmental entities, including U.S. federal governmental entities, and that
all Products offered for sale to the U.S. Government under this Agreement by MWI must be compliant with the Trade Agreements Act (TAA)
(19 U.S.C. 2501, et seq.) and certifies that all Products will be Country of Manufacture confirmed pursuant to TAA requirements. If Supplier
is not the actual manufacturer of the Products, Supplier certifies that it has supporting information on file from the manufacturer of
the Product to confirm compliance with the TAA and other Applicable Laws. If any previously provided information to MWI changes, Supplier
will provide 30 days’ prior written notice to MWI. Supplier understands that MWI is relying on Supplier’s certification to
meet its contractual obligations to the government. Supplier will work with MWI to comply in all material respects with all applicable
provisions of DSCSA, Title II of the Drug Quality and Security Act of 2013 and other Applicable Laws with respect to the Distribution
of the Products.

 

Supplier
is an equal opportunity employer and agrees that, as applicable, it will abide by the requirements of 41 CFR 60-1.4(a), 41 CFR 60-300.5(a)
and 41 CFR 60-741.5(a) and that these laws are incorporated herein by reference. These regulations prohibit discrimination against qualified
individuals based on their status as protected veterans or individuals with disabilities and prohibit discrimination against all individuals
based on their race, color, religion, sex, sexual orientation, gender identity, or national origin. These regulations require that covered
prime contractors and subcontractors take affirmative action to employ and advance in employment individuals without regard to race,
color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status or disability. Supplier also agrees
that, as applicable, it will abide by the requirements of Executive Order 13496 (29 CFR Part 471, Appendix A to Subpart A), relating
to the notice of employee rights under federal labor laws.

 

1.6
Code of Conduct. Supplier acknowledges that MWI is subject to the Code of Ethics and Business Conduct Policy (“Code of Conduct”)
issued by its parent company AmerisourceBergen, which Code of Conduct (as it may be revised from time to time) can be found at the Investors
tab, Corporate Governance, of www.amerisourcebergen.com. Supplier covenants that it either (a) will comply with MWI’s Code
of Conduct or (b) has and will comply with its own Code of Conduct that is substantially similar to MWI’s Code of Conduct, including
those sections on Fraud & Abuse Laws, Antitrust & Competition Laws and Anti-Bribery/Anti-Corruption Laws. In the event Supplier
violates the applicable Code of Conduct or any Applicable Laws related to fraud, abuse, antitrust, competition, anti-bribery or anti-corruption,
Supplier will be deemed to be in material breach of this Agreement.

 

    	Distribution Services Agreement – Exhibit B

    	 

    

 

1.7
Sales Force Compensation and Conflicts of Interest. Supplier shall not offer or provide to any employee or contractor of MWI,
including any member of MWI’s sales force or management, any payments, gifts, travel, entertainment, incentives or other benefits
(collectively, “Employee Incentives”), other than token, non-cash gifts of nominal value or typical business meals. If Supplier
wishes to provide any form of Employee Incentive to MWI’s employees, Supplier shall first discuss such Employee Incentives with
MWI and if MWI approves such Employee Incentives in its sole discretion, all such Employee Incentives shall be paid directly to and pass
through MWI and will be subject to reasonable deductions and fees and applicable taxes and withholdings.

 

1.8
Supporting Information. Supplier shall provide any documentation or instructions to MWI reasonably necessary for MWI to fully
comply with Applicable Laws with respect to the handling, storage and Distribution of the Products, including any documentation, certification
or instruction regarding the classification, handling and shipping of any hazardous materials, controlled substances and compliance with
the TAA and the California Safe Drinking Water and Toxic Enforcement Act of 1986. Supplier will maintain all federal, state or local
registrations necessary for the lawful manufacturing, packaging, labeling, marketing, handling and shipment of all Products, including
those deemed hazardous, and immediately notify MWI of any denial, revocation or suspension of any such registration or any changes in
the Products which MWI is authorized to distribute. To the extent the Products include any controlled substances, Supplier will provide
MWI with a copy of its U.S. Drug Enforcement Agency certificates and any other required documentation.

 

1.9
Warranties and Corrective Actions. Supplier shall be solely responsible and take all appropriate corrective actions for (a) Supplier’s
full or limited warranties relating to Products, (b) failure of a Product, and (c) Recalls except to the extent any such issues are caused
by MWI’s negligence or willful misconduct.

 

2.
MWI’S Responsibilities.

 

2.1
Efforts. MWI shall use commercially reasonable efforts in performing the Distribution Services for the Products in the Territory,
including determining (a) which Products to distribute and (b) the scope of the effort.

 

2.2
Stock Product. MWI shall make a good faith effort to maintain sufficient stock of Products to satisfactorily supply MWI’s
expected customer base demand.

 

2.3
Sales Force; Customer Service. MWI shall maintain a sales force to represent and promote the Products and provide prompt and effective
customer service regarding the Products.

 

    	Distribution Services Agreement – Exhibit B

    	 

    

 

2.4
Storage Conditions. MWI shall use commercially reasonable efforts to store the Products, both in storage and in-transit to MWI
customers, in accordance with instructions on the Product label.

 

2.5
Compliance with Laws. MWI shall store, ship and distribute the Products, as applicable, in compliance with all Applicable Laws.

 

2.6
Documentation. MWI shall, upon request with respect to any order for controlled substances, furnish Supplier with commercially
reasonable assurances that MWI is authorized to possess and distribute such controlled substances under federal law.

 

3.
Product Complaints; Recalls.

 

3.1
Product Complaints. Subject to any pharmacovigilance agreements between the parties, upon receipt by MWI of notice of (a) an adverse
drug experience, product defect, or manufacturing defect (as defined in 21 C.F.R. § 514.3) of the type that is reportable on FDA
Form 1932a or successor form, or (b) a lawsuit, in each case concerning a Product, MWI will promptly forward the notice to Supplier.
Upon completion of notice, MWI shall have no further obligation to Supplier concerning such event unless Supplier and MWI mutually agree
otherwise.

 

3.2
Product Recalls. If a recall, market withdrawal, field collection, corrective action, or similar action (“Recall”)
is implemented by Supplier or required by any federal, state, local or other regulatory or governmental authority with respect to any
Product sold under this Agreement, Supplier shall notify MWI and take all actions necessary to promptly execute the Recall, including
working with or through MWI regarding the Recall. Each Recall will be conducted and directed by Supplier, and MWI will follow Supplier’s
reasonable directions. For any Recall, Supplier shall directly pay or reimburse MWI for all reasonable costs, fees, and expenses, if
any, incurred by MWI (including reimbursement for pass through fees and time worked by MWI internal employees to manage the Recall, and
costs and expenses related to the shipping, notification and the repurchase of any Recalled Products in MWI’s possession); provided,
however, that Supplier shall not be responsible for reimbursing MWI for costs and expenses to the extent the Recall was caused by MWI’s
failure to handle and store the Products in accordance with instructions on the Product label. The patties will each retain complete
and accurate records as may be maintained in the ordinary course of business for all Products, including sales and service records, for
no less than the period of time required by Applicable Law, to facilitate any Recalls.

 

4.
Supplier Limited Warranties. Supplier
represents and warrants to MWI that (a) Supplier will operate, and all Products have been manufactured, labeled, packaged, stored, shipped
and distributed, in compliance with all Applicable Laws and applicable industry standards, (b) the Products are free and clear of any
defects in design, materials and workmanship and are not adulterated or misbranded, (c) Supplier has and will transfer to MWI good and
marketable title to the Products free and clear of all liens, claims, security interests or other encumbrances, (d) the Products conform
to the description, grade, condition, and specifications of the Products invoiced and may be legally transported and distributed in the
Territory by MWI under all Applicable Laws, (e) the Products do not infringe on or violate any patent, copyright, trademark, trade secret
or other intellectual property or proprietary right (“Intellectual Property Rights”) of any third party, and (f) Supplier
has all right and authority to appoint MWI as an authorized distributor of the Products (the “Limited Warranties”). Supplier
understands that these Limited Warranties will be passed through to any veterinarian, veterinary hospital, clinic, feedlot, integrator,
animal owner or other third-party end-user of the Product (“End-User”) and Supplier hereby issues the Limited Warranties
to such End Users. THE WARRANTIES SET FORTH HEREIN CONSTITUTE THE SOLE AND EXCLUSIVE WARRANTIES BY SUPPLIER WITH RESPECT TO THE PRODUCTS
AND SUPPLIER EXPRESSLY DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR
A PARTICULAR PURPOSE.

 

    	Distribution Services Agreement – Exhibit B

    	 

    

 

5.
Indemnification.

 

5.1
MWI’s Indemnification. MWI will defend, indemnify, and hold harmless Supplier, its affiliates and subsidiaries, and their
officers, directors and employees, from and against all damages, losses, costs, expenses (including reasonable attorney’s fees
and court costs), claims, judgments, and liabilities (“Claims”) to the extent arising out of (a) any violation of Applicable
Law by MWI; (b) breach of this Agreement by MWI; and/or (c) any actual or asserted fraud, negligence or willful misconduct of MWI except
to the extent arising from the fraud, negligence, willful misconduct of Supplier or Supplier’s breach of this Agreement or Applicable
Laws.

 

5.2
Supplier’s Indemnification. Supplier will defend, indemnify, and hold harmless MWI, its affiliates and subsidiaries, and
their officers, directors and employees, from and against all Claims arising as a result of (a) any actual or asserted third party claim
of a breach of the Limited Warranties; (b) any breach of this Agreement by Supplier; and/or (c) any actual or asserted fraud, negligence
or willful misconduct of Supplier except to the extent arising from the fraud, negligence, willful misconduct of MWI or MWI’s breach
of this Agreement or Applicable Laws. Contemporaneously with the execution of this Agreement, Supplier will execute and deliver to MWI
the Continuing Guaranty attached hereto as Schedule A. The representations, warranties and indemnification provisions contained in the
Continuing Guaranty are in addition to those contained herein.

 

5.3
Indemnification Procedure. If any written claim is made by any third party against a party to this Agreement for which such party
(“Indemnitee”) properly seeks indemnification, Indemnitee shall promptly notify the other party (“Indemnitor”)
and Indemnitor shall defend against the claim. Such notice will in any event be given within a reasonable period of time of becoming
aware of any claim against Indemnitee stating the nature and basis of such claim; provided, however, that any delay or failure to notify
Indemnitor of any claim will not relieve it from any liability except to the extent that Indemnitor demonstrates that the defense of
such action has been materially prejudiced by such delay or failure. Indemnitor will promptly notify Indemnitee of its intention to assume
the defense of such claim. If Indemnitor assumes the defense, it shall have sole control of the defense and all related settlement negotiations
and Indemnitee shall, at Indemnitor’s sole expense, provide Indemnitor with all reasonable assistance in connection with any claim.
Indemnitor shall consult with Indemnitee regarding the defense and shall provide Indemnitee with reasonably requested information. Indemnitor
may not settle any claim, suit, or proceeding in which Indemnitee is named or otherwise involved without Indemnitee’s prior written
consent, except in the case of a cash settlement payable by Indemnitor in which there is no admission or imposition of fault or liability
as to Indemnitee. If Indemnitor does not assume the defense of any such claim, Indemnitee may, at Indemnitor’s expense, defend
against such claim in such manner as Indemnitee may deem appropriate and settle such claim on such terms as it may deem appropriate,
and assert against Indemnitor any rights or claims to which Indemnitee is entitled.

 

    	Distribution Services Agreement – Exhibit B

    	 

    

 

6.
Confidentiality. Confidential Information
may be disclosed by one party (the “Disclosing Party”) to the other party (the “Receiving Party”) pursuant to
this Agreement. During the Term of this Agreement and for a period of one year from the date of termination or expiration of this Agreement,
the Receiving Party will not disclose, either directly or indirectly, such Confidential Information to any third party and only use such
Confidential Information for purposes of fulfilling its obligations under this Agreement. “Confidential Information” means
any confidential information furnished by the Disclosing Party that is conspicuously marked as “Confidential” (a) in the
subject line of the e-mail, if disclosure is by e-mail, and (b) on the first page of any paper or electronic copy of a disclosed document
in conspicuous print. Any information provided by or on behalf of MWI regarding MWI’s Distribution of the Products, including the
Sales Data (defined in Section 9 below), is confidential and proprietary information of MWI and may not be aggregated with other data,
sold or commercialized by Supplier unless such information meets the exclusions as defined below in this Section 6. If any information
is not so marked as “Confidential,” then the information is not Confidential Information. The term “Confidential Information”
does not include or apply to information that, as evidenced by existing documentation, (i) is or becomes generally available to and known
by the public, through no fault of the Receiving Party; (ii) is received by Receiving Party from a third party without any obligations
of confidentiality, or (iii) is independently developed by Receiving Party without use of or access or reference to Confidential Information.
Within 30 days after any written request by Disclosing Party, the Receiving Party shall return or destroy all physical and electronic
copies of the Confidential Information received from Disclosing Party and all materials that contain or reflect Confidential Information
created by Receiving Party. Notwithstanding anything in this Agreement to the contrary, the Receiving Party may retain Confidential Information
as and to the extent required by any applicable law, automatic back-up archiving practice, or bona-fide records retention policy, provided
that any Confidential Information so retained shall continue to be subject to the terms of this Agreement.

 

7.
Liability; Disputes.

 

7.1
Limitation of Liability. MWI and Supplier shall not be liable to each other for any special, incidental, consequential, punitive
or exemplary damages even if the parties have been made aware of the possibilities of such damages. Notwithstanding anything in this
Agreement to the contrary, no limitation or waiver of liability, damages, claims or remedies shall apply to any loss, damage, claim,
judgment, or liability related to a third party claim for which one party is obligated to indemnify the other party under this Agreement
and/or the Continuing Guaranty.

 

7.2
Dispute. If a dispute related to this Agreement, other than a breach of confidentiality, arises between the parties, the parties
shall first attempt to settle the dispute by direct discussions at the vice-president or higher level. If the dispute cannot be settled
by the parties by direct discussions, then the parties agree to endeavor to settle the dispute in an amicable manner by mediation administered
by the American Arbitration Association under its Commercial Mediation Rules. Thereafter, any unresolved dispute arising from or relating
to this Agreement shall be resolved as provided by this Agreement and by law.

 

    	Distribution Services Agreement – Exhibit B

    	 

    

 

8.
Payments. For purposes of determining
the timing of payment, payment will be deemed to have been made on the date MWI initiates the wire, ACH payment or other payment. Supplier
will not debit any MWI account electronically without MWI’s prior written consent. Supplier shall not make additions or surcharges
to any invoice amounts without MWI’s prior written consent. Supplier shall immediately remit any monies due to MWI in the event
of an MWI accounts payable debit balance situation with Supplier that persists for more than 10 days, including any debit balance arising
from chargebacks, rebates, credits, reimbursements, refunds, Distribution Services Fee, Redistribution Services Fee, backend margin,
or other incentives owed by Supplier (collectively, “Supplier Payables”). Debit balance is defined as the sum of all transactions
with Supplier in MWI’s accounts payable system, including Supplier Payables, having due dates through, but not extending beyond,
the then present date. If Supplier credits would no longer hold value to MWI, Supplier will issue cash in lieu of credit. MWI may set
off any amounts owed by Supplier to MWI, including Supplier Payables, against any amounts owed by MWI to Supplier. All amounts, payments
and credits contemplated by this Agreement are to be made in U.S. Dollars. For amounts past due, including Supplier Payables, the party
owed (“Claiming Party”) may charge the owing party (“Owing Party”) interest at an amount not to exceed the lesser
of (a) 12% per year or (b) the highest amount permitted by applicable law on any past due amounts that are not paid (or credited if permitted
in this Agreement) by the Owing Party within 10 days after receipt of written notice from Claiming Party that such amounts are past due.
Notwithstanding the foregoing, interest may not be charged on the portion of any amounts past due that are subject to a bona fide dispute
raised by the Owing Party prior to such amounts becoming past due, and not caused or contributed to by Owing Party’s lack of diligence.
The parties shall work in a timely manner and in good faith to resolve disputes.

 

9.
Sales Reporting. So long as Supplier is
in good standing, MWI shall report certain data to Supplier regarding the sales of the Products (“Sales Data”) to veterinary
practices on a mutually agreed format and time. The Sales Data shall include, but may not be limited to, (i) veterinary clinic and/or
veterinarian name, (ii) clinic and/or veterinarian business address, (iii) date of Product shipment to clinic and/or veterinarian, and
(iv) number of Product units delivered to clinic and/or veterinarian. This Sales Data is owned by MWI and MWI hereby grants Supplier
a limited license during the Term to use the Sales Data only for internal tracking and regulatory purposes, including production scheduling
and inventory management, regulatory quality control documenting and monitoring, and to calculate any Supplier Payables owed to MWI.
The use of Sales Data by Supplier and the extension of the limited license shall be allowed past the Term only for regulatory purposes.
Supplier is prohibited from using the Sales Data, in any manner whatsoever, to sell Products to MWI’s customers either directly
or through other distributors or intermediaries. This Section shall survive any termination or expiration of the Agreement. MWI may report
to Animalytix data regarding the sales of the Products and the sales of products of other manufacturers.

 

    	Distribution Services Agreement – Exhibit B

    	 

    

 

10.
Force Majeure. Each party’s obligation
under this Agreement will be excused to the extent any delay is caused by acts of God, war, terrorism, natural disaster or other conditions
beyond the reasonable control of that party, but only during the duration of such condition and provided such party gives prompt written
notice thereof to the other party. The nonperforming party shall take all reasonable steps to recommence performance as soon as possible.

 

11.
Governing Law; Venue. This Agreement shall
be governed by Delaware law without regard to its conflict of law provisions. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in Delaware for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein and hereby irrevocably waives, and agrees not to assert in any suit,
action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding
is improper or inconvenient venue for such proceeding.

 

12.
Taxes. MWI shall pay all sales and use
taxes attributable to MWI’s purchase of Products from Supplier, subject to Section 13. All other taxes, duties and fees applicable
to the Products, MWI’s purchase of the Products hereunder or any transaction contemplated by this Agreement shall be paid by Supplier,
including without limitation all taxes on Supplier’s income, import and export duties, excise fees, license fees, permit fees,
transfer fees, privilege fees and value added taxes.

 

13.
Reimbursement of Controlled Substance Tax Payments.
Notwithstanding any contrary provision of this Agreement, with respect to any current or future Product under this Agreement that is
classified as a “Controlled Substance” as defined by section 102 of the Controlled Substances Act, 21 U.S.C. § 802(6),
Supplier shall be responsible to reimburse MWI for any MWI paid tax, assessment, charge, fee, or other levy, regardless of how denoted
imposed by or payable to any federal, state, or local governmental agency or authority on, or in connection with, MWI’s purchase
(for inventory or drop-ship), distribution, sale or transfer of such Product based on the Product’s Controlled Substance classification
(collectively, a “Controlled Substance Tax”). If MWI is required by law to pay any Controlled Substance Tax, MWI shall provide
written notice to Supplier, which notice shall include a detailed invoice to Supplier, copies of state-specific invoices or MWI’s
official document submission of net distribution into each state, and calculations of Controlled Substance Tax paid based on distribution
reporting, and Supplier shall reimburse MWI for such undisputed invoices for Controlled Substance Tax by issuing a credit to MWI within
30 days of receiving that notice. All discrepancies in distribution data, Controlled Substance Tax, and late reimbursement shall be resolved
within 30 days through good faith discussions or meetings as necessary. If Supplier is required by law to pay any Controlled Substance
Tax, Supplier shall not pass on or otherwise invoice MWI for such Controlled Substance Tax as a separate line item or other charge specifically
identifiable as a Controlled Substance Tax. This Section 13 shall not apply to any generally applicable tax, assessment, charge, fee,
or other levy that does not discriminate on the basis of product type or category.

 

14.
Interpretation. The parties have jointly
negotiated this Agreement and, thus, neither this Agreement nor any provision will be interpreted for or against any party on the basis
that it or its attorney drafted this Agreement or the provision at issue. “Or” is disjunctive but not necessarily exclusive.
“Including” means “including but not limited to.”

 

15.
Successors; Assignments. All of the terms
and provisions of this Agreement will be binding on and inure to the benefit of the patties and their respective successors and assigns.
Neither party may assign, subcontract, delegate or transfer its rights or obligations hereunder without the prior written consent of
the other party.

 

16.
Severability. All provisions of this Agreement
are severable. If any term, provision, or agreement contained in this Agreement is held to be invalid, illegal, or unenforceable, the
remaining provisions of this Agreement shall remain valid, legal, and enforceable and be enforced and construed as if such invalid provision
were never a part of this Agreement.

 

17.
Independent Contractors. MWI and Supplier
are independent businesses with a vendor and vendee relationship. Neither party shall have, nor represent that it has, the power, right
or authority to bind the other party or to assume or to create any obligation or responsibility, express or implied, on behalf of the
other party. Nothing contained in this Agreement will be construed so as to characterize the relationship between the parties as a joint
venture, partnership, agency or franchise for any purposes whatsoever.

 

*      
*       *       *       *

 

    	Distribution Services Agreement – Exhibit B

    	 

    

 

Schedule
A

 

CONTINUING
GUARANTY AND INDEMNIFICATION AGREEMENT

 

The
undersigned guarantees to MWI Veterinary Supply Co. and each of its affiliate and subsidiary companies and any successors (collectively,
“MWI”) that (i) any food, drugs, devices, cosmetics, merchandise, or animal health related products (“Products”)
now or hereafter shipped or delivered by or on behalf of the undersigned, or any of its affiliates or subsidiary companies or any successors,
(collectively, “Guarantors”) to or on the order of MWI will not be at the time of delivery, adulterated, misbranded, or otherwise
prohibited under applicable federal, state and local laws, including applicable provisions of the Federal Food, Drug and Cosmetic Act,
21 U.S.C. §301 et seq. (“FDCA”), and Sections 351 and 361 of the Federal Public Health Service Act, 42 U.S.C. §§
262 and 264, and their implementing regulations, each as amended (collectively, “Applicable Laws”), in effect at the time
of shipment or delivery of such Products; (ii) Products are not, at the time of shipment or delivery, merchandise that may not otherwise
be introduced or delivered for introduction into interstate commerce under Applicable Laws, including FDCA section 301 (21 U.S.C. §331);
and (iii) Products are merchandise that may be legally transported or sold under the provisions of any other applicable federal, state
or local law. Guarantors guarantee further that, in the case of food shipments, only those chemicals or sprays approved by federal, state,
or local authorities have been used, and any residue in excess of the amount allowed by any such authorities has been removed from Products.

 

Guarantors
shall promptly defend, indemnify and hold MWI harmless against any and all claims, losses, damages, costs, liabilities and expenses,
including attorneys’ fees and expenses, arising as a result of (a) any actual or asserted violation of Applicable Laws or by virtue
of which Products made, sold, supplied, or delivered by or on behalf of Guarantors may be alleged or determined to be adulterated, misbranded
or otherwise not in full compliance with or in contravention of Applicable Laws, (b) the possession, distribution, sale and/or use of,
or by reason of the seizure of, any Products of Guarantors, including any prosecution or action whatsoever by any governmental body or
agency or by any private party, including claims of bodily injury, death or property damage, (c) any actual or asserted claim that Guarantors’
Products infringe any proprietary or intellectual property rights of any person, including infringement of any trademarks or service
names, trade names, trade secrets, inventions, patents or violation of any copyright laws or any other applicable federal, state or local
laws, and (d) any actual or asserted claim of negligence, willful misconduct or breach of contract except to the extent arising from
the negligence, willful misconduct or breach of contract of MWI.

 

Guarantors
shall maintain primary, noncontributory product liability insurance of not less than $5 million per occurrence for claims relating to
Products. This insurance must include “MWI Veterinary Supply Co. and each of its affiliate and subsidiary companies and any successors”
as additional insureds for claims arising out of Products. Guarantor shall provide for at least thirty days’ advance written notice
to MWI Veterinary Supply Co. of cancellation or material reduction of the required insurance. If the required insurance is underwritten
on a “claims made” basis, the insurance must include a provision for an extended reporting period (“ERP”) of
not less than twenty-four months; Guarantors further agree to purchase the ERP if continuous claims made insurance, with a retroactive
date not later than the date of this Agreement, is not continually maintained or is otherwise unavailable. This insurance shall be with
an insurer and in a form acceptable to MWI Veterinary Supply Co., and any deductible or retained risk must be commercially and financially
reasonable and acceptable to MWI Veterinary Supply Co. Guarantors warrant that they have sufficient assets to cover any self-insurance
or retained risk. Upon request, Guarantors will promptly provide satisfactory evidence of the required insurance.

 

Provisions
in this Continuing Guaranty and Indemnification Agreement are in addition to, and not in lieu of, any terms set forth in any purchase
orders accepted by Guarantors or any separate agreement entered into between MWI and Guarantors. If the language in this Agreement conflicts
with the language in any other document, the language in this Agreement controls.

 

	 	Supplier: PetVivo, Inc.
	 	 	 
	 	Signature:	/s/
    John Lai
	 	 	 
	 	Name:	John Lai
	 	 	 
	 	Title:	Chief Executive Officer
	 	 	 
	 	Date:	June 15, 2022

 

 

    	CGIA – Schedule ADocument

Rich Preece 
delivered via email 
Dear Rich: 
On behalf of LegalZoom.com, Inc., a Delaware corporation (the “Company”), I am pleased  to provide you an offer of continuing employment with the Company pursuant to the terms and  conditions set forth in this letter (this “Agreement”). All capitalized terms not otherwise defined  shall have the definition and meaning provided in Section 17. 
1. Title; Duties; Reporting. You will serve as the Company’s Chief Product Officer (“CPO”)  and shall report directly to the Company’s Chief Executive Officer (“CEO”). You shall be a  member of the Company’s senior management team and shall have such duties and responsibilities  as shall be consistent with your position. You will also devote your full time, efforts, abilities, and  energies, except for as permitted in Section 1(b) below and except for approved vacation periods  and reasonable periods of illness or other incapacities permitted by the Company’s general  employment policies, to promote the general welfare and interests of the Company and any related  enterprises of the Company. You will loyally, conscientiously, and professionally do and perform  all duties and responsibilities of your position, as well as any other duties and responsibilities as  will be reasonably assigned to you by the Company and modified as the Company deems necessary  and appropriate in light of the Company’s needs and interests from time to time, consistent with  your position and this Agreement. You will strictly adhere to and obey all Company rules, policies,  procedures, regulations and guidelines including, but not limited to, those contained in the  Company’s employee handbook, as well as any others that the Company may establish. You will  strictly adhere to all applicable state and/or federal laws and/or regulations relating to your  employment with the Company. 
(a) No Conflicting Obligations. By signing this Agreement, you confirm to the  Company that you have no contractual commitments or other legal obligations that would prohibit  you from performing your duties for the Company or executing this Agreement. 
(b) Outside Activities. You may (i) serve as a director or member of a committee or  organization involving no actual or potential conflict of interest with the Company and its  subsidiaries and affiliates; (ii) deliver lectures and fulfill speaking engagements; (iii) engage in  charitable and community activities; and (iv) invest your personal assets in such form or manner  that will not violate this Agreement; provided, however, that the activities described in clauses (i),  (ii), (iii) and (iv) do not materially affect, interfere, or create an actual or potential conflict of  interest with the performance of your duties and obligations to the Company, and further provided  that the Company’s Board of Directors (the “Board”) must provide its advance written consent  with respect to the items referenced in clause (i) which consent the Board may provide or withhold  in its discretion.
2. Term. 
(a) Term of Agreement. This Agreement and your employment under the terms  hereunder shall take effect immediately prior to, and contingent upon, the effectiveness of the  registration statement on Form S-1 filed with the Securities and Exchange Commission for the  initial public offering of the Company’s common stock (the “Effective Date”). Notwithstanding  the foregoing, in the event you do not remain employed with the Company through the Effective  Date or the Effective Date does not occur, this Agreement will have no effect, will not be binding  on the Company (or any of its affiliates) or on you, and neither you nor the Company (or any of  

its affiliates) shall have rights or obligations hereunder. The period from the Effective Date until  the termination of your employment under this Agreement is hereinafter referred to as “the term  of this Agreement” or “the term hereof” or “the Term.”  
(b) Resignation. Upon termination of your employment for any reason, you shall be  deemed to have immediately resigned from all positions as an employee, officer and/or director  with the Company, and any of its affiliates, as of your last day of employment (the “Termination  Date”). This Agreement shall serve as notice of such resignations by you; provided, however, you 
agree to execute any documents that the Company may reasonably request evidencing such  resignations. 
3. Compensation. 
(a) Base Salary. As of the Effective Date, your base salary shall be $300,000 per year,  less applicable withholdings and deductions, payable in accordance with the Company’s standard  payroll procedures. The base salary as determined herein and adjusted from time to time shall  constitute the “Base Salary” for purposes of this Agreement. 
(b) Performance Bonus. During each fiscal year of the Company during the Term, you  will be eligible to earn a cash performance bonus (“Performance Bonus”) with a target amount of  50% of your Base Salary for the applicable fiscal year of the Company. Your actual bonus for any  fiscal year, if any, shall be based on the successful completion of the performance objectives (the  “Objectives”) that are prescribed and established by the Board (or its compensation committee) in  its discretion, in consultation with the Company’s Chief Executive Officer and you. The Objectives  will be established each year no later than thirty (30) days after the start of the applicable bonus  period. Except as set forth in Section 4(a), to earn and receive any Performance Bonus, you must  remain employed by the Company through the date of each of the Performance Bonus payment(s)  and the termination of your employment for any reason before such payment date means you will  not receive such payment. 
(c) Company-Sponsored Benefits. As a member of the senior management team of the  Company, you will also be eligible to receive all employee benefits pursuant to the Company’s  standard benefit plans that the Company generally provides to the other members of the senior  management team that may be in effect from time to time. These currently include, without  limitation, group health benefits, 401(k) retirement benefits, business expense reimbursements,  PTO, sick time and Company paid holidays. 
(d) Indemnification and D&O Insurance. You shall be entitled to indemnification for  losses incurred in connection with your service as an officer or employee (including coverage  under applicable D&O insurance policies) on terms no less favorable than any other senior  executive of the Company. 
(e) Equity Compensation. 
(i) Stock Options. You and the Company acknowledge and agree that on  January 6, 2020, the Board granted you stock options under the Company’s 2016 Stock Incentive  Plan, as amended (the “2016 Plan”), providing you the opportunity to benefit from future  appreciation with respect to 1.2% fully diluted ownership in the Company as of the date of the  grant (determined on an as-converted basis and inclusive of shares reserved for issuance under any Company equity compensation plan) (the “Equity Award”). The Equity Award shall vest with  respect to 5/12th of such 1.2% (0.5% of the fully diluted ownership in the Company, such portion  referred to herein as the “Time-Based Options”) quarterly over 4 years (from December 2, 2019,  with a 12-month cliff (meaning amounts that otherwise would vest during the first 12 months 

shall  be scheduled to vest on December 2, 2020). If during the twenty-four (24) month period following a Change in Control your employment is terminated without Cause by the Company or by you for  Good Reason, then 100% of the Time-Based Options shall be fully vested upon such termination. 
The Equity Award shall vest with respect to the remaining 7/12th of such 1.2% (the portion that is not the Time-Based Options, such portion, the “Performance Options”) in accordance with the  amended vesting schedule set forth in Section 3(e)(ii) below. All vesting is subject to your  continued employment with the Company through the applicable vesting date or event. Except as  described in this Section 3(e)(i), the Equity Award reflects the Company’s standard terms and  conditions for grants of equity compensation. For the avoidance of doubt, in the event of an  extraordinary dividend, the Company shall make equitable adjustments to the Equity Award or  provide equivalent cash payments to you (which may be subject to the same vesting schedule as 
applicable to the Equity Award) in lieu of adjustment. You and the Company acknowledge and  agree that on September 23, 2020, the Board reduced the per share exercise price of both the Time Based Options and Performance Options to $9.82 (the then-current fair market value of a share of  the Company’s common stock). The stock option agreement that governs the Time-Based Options  and the stock option agreement that governs the Performance Options are referred to herein as the  “Service-Based Option Agreement” and the “Performance Option Agreement,” respectively. 
(ii) Amendment to Performance Options. By signing this Agreement, you agree  that the “Vesting Schedule” section in the “Notice of Stock Option Grant” in Part I of the Performance Option Agreement is hereby amended and restated in its entirety to read as follows: 
“Vesting Schedule: This Option shall vest according to the following schedule: 
One forty-eighth (1/48th) of the Shares subject to the Option shall vest each  month following November 15, 2019 (the “Vesting Commencement Date”) on the same day of the month as the Vesting Commencement Date (and if  there is no corresponding day, on the last day of the month), subject to  Optionee continuing to be a Service Provider through each such date.”
Except as expressly amended by this section 3(e)(ii), the Performance Option Agreement (as defined above) shall be unaffected hereby and shall remain in full force and effect. For clarity,  the terms of the Time-Based Options, including those set forth in the Service-Based Option  Agreement, shall not be affected by the foregoing amendment of the Performance Options and  shall remain in full force and effect. 
(iii) RSUs. You and the Company acknowledge and agree that on September 23,  2020, the Board granted you restricted stock units under the 2016 Plan with a grant date value of  $2,000,000 (the “RSUs”). The RSUs reflect the Company’s standard terms and conditions for  grants of restricted stock units; provided, however, that the RSUs shall vest only upon the  achievement of both a Liquidity Event (as defined below) condition and a service-based condition.  The RSUs shall satisfy the service-based condition quarterly over 4 years (from November 15,  2019) with a 12-month cliff (meaning amounts that otherwise would satisfy the service-based  condition during the first 12 months shall be scheduled to satisfy the service-based condition on  the first anniversary of November 15, 2019), subject to your continued employment with the  Company through each date on which the service-based condition is scheduled to be satisfied. In  the event that your employment is terminated without Cause by the Company or by you for Good  Reason outside of the Change in Control Period, then the number of RSUs that otherwise would  have met the service-based condition had you remained employed by the 

Company through the  twelve (12)- month anniversary of the date of such termination of your employment shall be  deemed to immediately meet the service-based condition. The Liquidity Event condition will be  deemed to have been met as of the occurrence of a Liquidity Event. For purposes of vesting of the  RSUs, a “Liquidity Event” shall be deemed to occur on the first to occur of (i) a Change in Control,  or (ii) a Public Trading Date (as defined in the 2016 Plan). For the avoidance of doubt, if the  Liquidity Event condition is satisfied before the completion of the service-based condition, the  RSUs shall continue to vest in accordance with the original service-based vesting schedule (and  shall be settled immediately upon each such service-based vesting date). For the further avoidance  of doubt, if your employment terminates for any reason other than for Cause, you shall retain any  service-vested RSUs until the expiration of the term of the RSUs (which, to comply with Section  409A, shall be 6.5 years from the date of grant) or the earlier settlement of the service-vested RSUs  upon satisfaction of the Liquidity Event condition. 
(iv) IPO RSUs. At the Effective Date, you will be granted restricted stock units (each, an “IPO RSU” and collectively, the “IPO RSUs”) with an approximate grant date value of  $2,000,000 (the “IPO RSUs Grant Date Value”), subject to both (A) approval by the Board or the  Compensation Committee of the Board (the “Compensation Committee”), and (B) you remaining  employed through the grant date of the IPO RSUs. Each IPO RSU will cover one share of the  Company’s common stock, and the aggregate number of IPO RSUs will be calculated by dividing  the IPO RSUs Grant Date Value by the initial per share price to the public as set forth in the final  prospectus included within the registration statement on Form S-1 filed with the Securities and  Exchange Commission for the initial public offering of the Company’s common stock, provided  that any fractional restricted stock unit resulting from such division will be rounded down to the  nearest whole unit. The IPO RSUs shall be granted under the 2016 Plan and the Company’s  standard form of restricted stock unit agreement approved by the Board for use thereunder. Subject  to Section 4(a) below and the terms of the 2016 Plan, twenty-five percent (25%) of the IPO RSUs  shall vest on the one-year anniversary of the Vesting Commencement Date (as defined below),  and one-twelfth (1/12th) of the remaining IPO RSUs shall vest on each of the next twelve (12) 
Quarterly Vesting Dates thereafter, subject to your continuous status as a Service Provider (as  defined in the 2016 Plan) on each vesting date. The “Vesting Commencement Date” shall mean  the first Quarterly Vesting Date following the Effective Date, provided if the Effective Date occurs  on a Quarterly Vesting Date, the Vesting Commencement Date shall mean the Effective Date.  “Quarterly Vesting Dates” shall mean each of February 15, May 15, August 15, and November  15; provided, however, that to the extent any such date occurs on a weekend day or U.S. federal  holiday, the Quarterly Vesting Date will be deemed to occur on the immediately following day  that is not a weekend day or U.S. federal holiday.  
(v) IPO Option. At the Effective Date, you will be granted a stock option to purchase shares of the Company’s common stock (the “IPO Option”), subject to both (A) approval  by the Board or the Compensation Committee, and (B) you remaining employed through the grant  date of the IPO Option. The aggregate number of shares subject to the IPO Option will be  calculated by multiplying the aggregate number of IPO RSUs by 2.5, provided any fractional  share resulting from such multiplication will be rounded down to the nearest whole share. The  IPO Option will have a per share exercise price equal to 100% of the fair market value of a share  of the Company’s common stock on the date of grant, as determined by the Board or the  Compensation Committee in its sole discretion. The IPO Option shall be granted under the 2016  Plan and the Company’s standard form of stock option agreement approved by the Board for use  thereunder. Subject to Section 4(a) below and the terms of the 2016 Plan, twenty-five percent  (25%) of the shares of the Company’s common stock subject to the IPO Option shall vest on the  one-year anniversary of the Vesting Commencement Date (as defined above), and one-twelfth  (1/12th) of the remaining shares 

of the Company’s common stock subject to the IPO Option shall  vest on each of the next twelve (12) Quarterly Vesting Dates (as defined above) thereafter, subject  to your continuous status as a Service Provider (as defined in the 2016 Plan) on each vesting date.  
4. Termination of Employment. Notwithstanding anything to the contrary in this Agreement, whether express or implied, your employment with the Company is at-will and the  Company may at any time terminate your employment with the Company and the Term, for any  reason or no reason, and with or without Cause, and you may resign from your employment with  or without Good Reason and terminate the Term, in each case subject to the terms and provisions  of this Agreement, and all as set forth in greater detail in this Section 4. If your employment  terminates due to your resignation without Good Reason or by the Company for Cause, then you  will not be eligible for any severance benefits. You shall receive payment from the Company of  the Accrued Obligations through the Termination Date upon the termination of your employment  for any reason.  
(a) Severance and Other Termination Benefits. Subject to Section 4(a)(iv), if during the Term there is a Qualifying Termination or your employment with the Company terminates as  a result of your death or Disability, then you shall be eligible to receive the following payments  and benefits (as applicable, the “Severance Benefits”): 
(i) Qualifying Termination Outside of the Change in Control Period. In the event you have a Qualifying Termination that occurs outside of the Change in Control Period, the  Severance Benefits shall consist of the following: 
(A) cash severance payments of twelve (12) months’ continued Base Salary, subject to all applicable deductions and withholdings, paid in accordance with the  Company’s standard payroll schedule over a period of twelve (12) months; provided, however (x)  amounts shall accrue until the Release (as defined below) becomes fully and irrevocably effective,  and (y) in the event the Release Period spans two calendar years, no amount of such cash severance  payments will be paid prior to January 1 of the second calendar year; and 
(B) to the extent permitted by applicable laws without incurring statutory penalties, the Company will reimburse the cost (to the same extent that the Company was  paying as of immediately before the Termination Date) for all group employee health benefits  coverage continuation under the Consolidated Omnibus Budget Reconciliation Act of 1985, as  amended (“COBRA”) to the same extent provided by the Company’s group health plans  immediately before the Termination Date (“COBRA Benefits”) for twelve (12) months after the  Termination Date or until you become eligible for group health insurance benefits from another  employer, whichever occurs first, provided that you timely elect COBRA coverage. You agree (i)  at any time either before or during the period of time you are receiving the COBRA Benefits to  inform the Company promptly in writing if you become eligible to receive group health coverage  from another employer and to respond to any Company inquiries confirming that you did not  become eligible for other coverage; and (ii) that you may not increase the number of your  designated dependents, if any, during this time unless you do so at your own expense. The period  of such COBRA Benefits shall be considered part of your COBRA coverage entitlement period.  Reimbursement for the COBRA Benefits shall be provided to you within sixty (60) days of your  submission of evidence of the premium payment, subject to such submission being delivered to  the Company within sixty (60) days of your making the applicable payment; and 
(C) immediate vesting acceleration of the Time-Based Options and Performance Options to the extent outstanding and unvested as of the date of your Qualifying  Termination, in each case as to the number of shares of the Company’s common stock subject to  such award that otherwise 

would have vested had you remained employed by the Company  through the twelve (12)- month anniversary of the date of your Qualifying Termination; and 
(D) the Time-Based Option, Performance Options and IPO Option to the extent outstanding and vested as of the date of your Qualifying Termination (after giving effect to  the vesting acceleration described in subpart (C) above and any other applicable vesting  acceleration) shall each remain outstanding and exercisable until the earlier of (i) the expiration of  the original term of such stock option, (ii) the one-year anniversary of the date of your Qualifying  Termination, provided if such stock option is the IPO Option, then the 90th day following your  Qualifying Termination instead, and (iii) immediately prior to the effective time of a Change in  Control if such stock option is not assumed, continued or substituted by the surviving or acquiring  entity (or its parent) in connection with such Change in Control.
(ii) Qualifying Termination During the Change in Control Period. In the event  you have a Qualifying Termination that occurs during the Change in Control Period, the Severance  Benefits shall instead consist of the following: 
(A) a cash severance payment equal to the sum of: (i) twelve (12) months’ of  your Base Salary plus (ii) a cash payment equal to your Performance Bonus at target level for the  fiscal year of the Company in which your Qualifying Termination occurs, subject to all applicable  deductions and withholdings, paid as a one-time, lump-sum payment on the first regularly 
scheduled Company payroll date falling after the date the Release becomes fully and irrevocably  effective, provided that in the event the Release Period spans two calendar years, no amount of  such cash severance payment will be paid prior to January 1 of the second calendar year; and 
(B) the COBRA Benefits, subject to the same terms and conditions set forth in  Section 4(a)(i)(B); and 
(C) immediate vesting acceleration of one hundred percent (100%) of the  Performance Options, RSUs, IPO RSUs and IPO Option to the extent outstanding and unvested as  of the date of your Qualifying Termination; and 
(D) the Time-Based Options, Performance Options and IPO Option to the extent  outstanding and vested as of the date of your Qualifying Termination (after giving effect to the  vesting acceleration described in subpart (C) above and any other applicable vesting acceleration) shall each remain outstanding and exercisable until the earlier of: (i) the expiration of the original  term of such stock option, (ii) the one-year anniversary of the date of your Qualifying Termination,  and (iii) immediately prior to the effective time of a Change in Control if such stock option is not  assumed, continued or substituted by the surviving or acquiring entity (or its parent) in connection  with such Change in Control. 
(iii) Termination of Employment due to Death or Disability. In the event your  employment with the Company terminates as a result of your death or Disability, the Severance  Benefits shall instead consist of the following: (A) the Time-Based Options, Performance Options,  RSUs, IPO RSUs and IPO Option to the extent unvested and outstanding immediately prior to  such termination of your employment shall immediately become fully vested and, as applicable, 
exercisable; and (B) the Time-Based Options, Performance Options and IPO Option to the extent  vested and outstanding on the date of such termination of your employment (after giving effect to  the vesting acceleration provided for in clause (A) above and any other applicable vesting  acceleration) shall remain outstanding and exercisable until the earlier of: (i) the expiration of the  original term of such stock option, (ii) the one-year anniversary of the date of your termination of  

employment with the Company, and (iii) immediately prior to the effective time of a Change in  Control if such stock options are not assumed, continued or substituted by the surviving or  acquiring entity (or its parent) in connection with such Change in Control. 
(iv) Release of Claims. Notwithstanding anything to the contrary, in order to  receive any Severance Benefits, you (or after your death, your estate) must timely execute and  deliver (and not revoke) a separation agreement and general release of claims in favor of the  Company, any affiliates or related entities, and their employees and affiliates, substantially in the  form and content attached as Exhibit A hereto (the “Release”), within the time period specified in 
the release, but in any event such release must become effective by its terms by no later than the  55th day following the Termination Date (such time period, extended by an additional 7 days, the  “Release Period”). For the avoidance of doubt, in no event shall you be eligible to receive  Severance Benefits pursuant to both Section 4(a)(i) and Section 4(a)(ii) and you are not eligible to  receive any Severance Benefits in the event your employment is terminated as a result of your  death or Disability other than as provided for in Section 4(a)(iii). You shall receive payment or  benefits from the Company of the Accrued Obligations, as applicable, regardless of whether a  separation agreement and general release of claims in the form and content attached as Exhibit A hereto is executed and timely provided to the Company. 
(b) Termination for Cause. The Company may terminate your employment and the  Term at any time for Cause. In the event you are provided written notice of a potential termination  for Cause (subject to any cure period), your right to exercise any equity compensation award (and  the vesting or settlement of any equity compensation award) shall automatically be suspended  during the cure period (if any). Upon the termination of your employment for Cause, you shall not  be entitled to exercise any outstanding equity compensation award whatsoever and all of your  outstanding equity compensation awards (both vested and unvested) shall automatically terminate  without consideration. Any determination by the Company with respect to the foregoing shall be  final, conclusive and binding on all interested parties. Any termination for Cause will not limit any  other right or remedy the Company may have under this Agreement or otherwise. 
(c) Termination without Cause. The Company shall have the unilateral right to  terminate your employment and the Term at any time without Cause, and without notice, in the  Company’s sole and absolute discretion. Any such termination without Cause shall not constitute  a breach of any term of this Agreement, express or implied, or a wrongful deprivation of your  office or position. If the Company terminates your employment and the Term without Cause, it  shall be treated as a Qualifying Termination and the Company shall have no obligation to you,  except to pay you (or cause to occur, if applicable) the amounts (and actions) set forth in Section  4(a) above in accordance with the terms thereof. 
(d) Termination due to Death. Your employment and the Term will be automatically  terminated on the date of your death. 
(e) Termination due to Disability. If you are subject to a Disability, and if within thirty  (30) days after written notice is provided to you by the Company you shall not have returned to  fully perform your duties, your employment and the Term, upon a second written notice from the  Company, will be terminated for Disability as of the date set forth in such second written notice. 
(f) Resignation for Good Reason. You may terminate your employment and the Term at any time for Good Reason; provided that you provide the Company with written notice within  thirty (30) days of the date of the initial existence of the purported Good Reason event and such  

notice must describe in detail the basis and underlying facts supporting your belief that a Good  Reason event has occurred (the “Good Reason Notice”). Failure to timely provide such Good  Reason Notice to the Company means that you will be deemed to have consented to and  irrevocably waived that particular potential Good Reason event. After its receipt of the Good  Reason Notice, the Company shall then have sixty (60) days to cure or remedy the alleged Good  Reason event. If the Company does cure or remedy the alleged Good Reason event during such 
sixty (60) day period then the Good Reason event will be deemed to have not occurred. If the  Company does not cure or remedy the Good Reason event during such sixty (60) day period then  your employment with the Company shall be automatically terminated for Good Reason as of the  day following the expiration of the sixty (60) day cure/remedy period. If you terminate your  employment for Good Reason in accordance with the provisions of this Section 4(f), it shall be  treated as a Qualifying Termination and the Company shall pay you (or cause to occur, if  applicable) the amounts (and actions) set forth in Section 4(a) above in accordance with the terms  thereof and any related provisions of this Agreement. 
(g) Resignation without Good Reason. You may terminate your employment and the Term at any time for no reason, or for any reason that does not otherwise constitute Good Reason,  in your sole and absolute discretion, but only if you provide written notice to the Company at least  fifteen (15) days prior to the effective date of your intended resignation date (and such notice must  specify the effective date of your resignation of employment). In the event you so terminate your  employment without Good Reason, you shall only be entitled to receive (subject to Section 14  below) the Accrued Obligations through the Termination Date and neither you nor the Company  shall have any further obligations to the other except as set forth in Sections 6 through 15. 
(h) The Company is not obligated to employ your services (nor compensate you) for any length of time beyond the fifteen (15) day period commencing from the date of your written  notice to the Company of your intended resignation. Further, the Company is not obligated to  actually utilize your services at any time during such period commencing from the date of your  written notice to the Company of your intended resignation through the Termination Date, and the  Company may prevent you from accessing any of the Company’s premises or resources during  such period. 
5. Golden Parachute Excise Tax. 
(a) In the event that it shall be determined that any payment, distribution or other action by the Company to or for your benefit (whether paid or payable or distributed or distributable  pursuant to the terms of this Agreement or otherwise, (a “Payment”)) would be subject to any  excise tax (an “Excise Tax”) imposed by Section 4999 of the Internal Revenue Code of 1986, as  amended (the “Code”), and if, immediately prior to the Relevant 280G Event (as defined below),  the Payments are eligible for the shareholder approval exemption under Section 280G(b)(5)(B) of  the Code, then: (i) the Company shall submit the Payments for shareholder approval to the extent  necessary for no Excise Tax to be due and (ii) you shall execute such releases or other documents  necessary to seek to obtain the requisite shareholder approval in a manner satisfying  Section 280G(b)(5)(B) of the Code. For purposes of this Section 5, “Relevant 280G Event” means  the relevant change in ownership or effective control, or change in the ownership of a substantial  portion of the assets, of a corporation (all within the meaning of Section 280G of the Code), that  will or may result in Payments becoming subject to the Excise Tax. 
(b) In the event that the payments are not eligible for the shareholder approval exemption under Section 280G(b)(5)(B) of the Code, then the Payments shall be payable as to such  less amount which would result in no portion of such payments or distributions being subject to  the Excise 

Tax; provided, however, that no such reduction shall be made if the net after-tax amount  (after taking into account federal, state, local or other income, employment and excise taxes) to 
which you would otherwise be entitled without such reduction would be greater than the net after tax amount (after taking into account federal, state, local or other income, employment and excise  taxes) to you resulting from the receipt of such payments and benefits with such reduction. 
(c) If a reduction in the Payments is necessary so that no Payment is subject to the  Excise Tax, the reduction shall occur in the following order: (1) reduction of cash payments for  which the full amount is treated as a parachute payment; (2) cancellation of accelerated vesting  (or, if necessary, payment) of cash awards for which the full amount is not treated as a parachute  payment; (3) cancellation of any accelerated vesting of equity compensation awards; and (4)  reduction of any continued employee benefits. In selecting the equity compensation awards (if  any) for which vesting will be reduced under clause (3) of the preceding sentence, awards shall be  selected in a manner that maximizes the after-tax aggregate amount of the Payments provided to  you; provided, that, if (and only if) necessary in order to avoid the imposition of an additional tax  under Section 409A (as defined below), awards instead shall be selected in the reverse order of the  date of grant. For the avoidance of doubt, for purposes of measuring an equity compensation  award’s value to you, such award’s value shall equal the then aggregate fair market value of the  vested shares underlying the award less any aggregate exercise price less applicable taxes. Also, if  two or more equity compensation awards are granted on the same date, each award will be reduced  on a pro-rata basis. In no event shall you have any discretion with respect to the ordering of  payment reductions. 
(d) In no event will the Company be required to gross up any payment or benefit to you  to avoid the effects of the Excise Tax or to pay any regular or excise taxes arising from the  application of the Excise Tax. 
(e) All mathematical determinations and all determinations of whether any of the  Payments are “parachute payments” (within the meaning of Section 280G) that are required to be  made under this Section 5, shall be made by a nationally recognized independent audit firm, law  firm or other advisor selected by the Company (the “Advisors”), who shall provide their  determination, together with detailed supporting calculations regarding the amount of any relevant  matters, both to the Company and to you. Such determination shall be made by the Advisors using  reasonable good faith interpretations of the Code. Any determination by the Advisors shall be  binding upon the Company and you, absent manifest error. 
6. Expense Reimbursement. You shall be reimbursed for all documented reasonable business  expenses that are incurred in the ordinary course of business upon the properly completed and  timely submission of requisite forms and receipts to the Company in accordance with the  Company’s expense reimbursement policy as in effect from time to time. 
7. Confidential Information. 
(a) As an employee of the Company, you will have access to certain confidential  information of the Company and you may, during the course of your employment or thereafter,  develop certain information or inventions which will be the property of the Company. You acknowledge that you will be making use of, acquiring and/or adding to confidential information.  The confidential information is and will remain the sole and exclusive property of the Company.  You will not at any time use, divulge, disclose or communicate, either directly or indirectly, in any 
manner whatsoever, any confidential information to any person or business entity, or remove from  the premises of the Company any confidential information in whatever form, unless 

required by  you to perform the essential functions of your position with the Company while employed by the  Company. 
(b) In consideration of, and as a condition to, your continued employment with the  Company, and as an essential inducement to the Company to enter into this Agreement, this  Agreement is expressly subject to your continued compliance with the Confidential Information  and Employee Invention Assignment Agreement (the “Confidentiality Agreement”) between you  and the Company attached hereto as Exhibit B (but with such changes as the Company may  determine are necessary to reflect changes in applicable law). You will fully comply with all  obligations under the Confidentiality Agreement and further agree that the provisions of such  agreement shall survive any termination or expiration of this Agreement or termination of your  employment. 
8. Covenants. You and the Company (as applicable) agree to timely and fully comply with all  of the covenants set forth in this Section 8 and further understand and agree that such covenants  (in addition to Sections 5 and 9 through 15) shall survive any termination of your employment and  termination or expiration of this Agreement. 
(a) Return of Company Property. On your Termination Date, or at any other time as  required by the Company, you will immediately surrender to the Company all Company property,  including, but not limited to, Confidential Information (as such term is defined in the  Confidentiality Agreement), keys, key cards, computers, telephones, pagers, credit cards,  automobiles, equipment, and/or other similar property of the Company. 
(b) Non-Solicit. During your employment with the Company and for twelve (12)  months after your Termination Date, but only to the extent permitted by applicable law, you shall  not, directly or indirectly, either as an individual or as an employee, agent, consultant, advisor,  independent contractor, general partner, officer, director, stockholder, investor, lender, or in any  other capacity whatsoever, of any person, firm, corporation or partnership: (i) solicit, induce,  recruit or encourage any of the Company’s employees or consultants to terminate their relationship  with the Company, or (ii) attempt to solicit, induce, recruit, or encourage any of the Company’s  employees or consultants to terminate their relationship with the Company, or (iii) attempt to  solicit, induce, recruit, encourage or take away employees or consultants of the Company. A  general advertisement for employment not targeted at any specific individual shall not constitute  a violation of this Section 8(b).  
(c) Nondisclosure. Notwithstanding any requirement that the Company may have to  publicly disclose the terms of this Agreement (and its exhibits) pursuant to applicable law or  regulations, you agree to use reasonable efforts to maintain in confidence the existence of this  Agreement, the contents and terms of this Agreement, and the consideration for this Agreement  (hereinafter collectively referred to as “Agreement Information”). You also agree to take every  reasonable precaution to prevent disclosure of any Agreement Information to third parties, except  for disclosures required by law or absolutely necessary with respect to your immediate family  members or personal advisors who shall also agree to maintain the confidentiality of the  Agreement Information.
(d) Cooperation. You agree that, upon the Company’s request, during the five (5) years  immediately following your termination of employment with the Company you shall reasonably  cooperate with the Company (and be available as reasonably necessary) after the Termination Date  in connection with any matters involving events that occurred during your period of employment  with the Company. When making requests for you to assist with matters involving 

events that  occurred during your period of employment with the Company, the Company agrees to reasonably  accommodate your schedule. 
(e) Amounts Due. You will fully pay off any outstanding amounts owed to the  Company no later than their applicable due date or within thirty (30) days of the Termination Date  (if no other due date has previously been established). Within thirty (30) days of the Termination  Date, you will submit any outstanding business expense reports to the Company for business  expenses incurred prior to the Termination Date. 
(f) Company Resources. As of the Termination Date, or at any other time as required  by the Company, you will no longer represent that you are an officer, director or employee of the  Company or any Company affiliate and you will immediately discontinue using the Company  mailing address, telephone, facsimile machines, voice mail and e-mail. 
(g) Representations. You represent that you have not entered into any agreements,  understandings, or arrangements with any person or entity that you would breach as a result of, or  that would in any way preclude or prohibit you from entering into, this Agreement with the  Company or performing any of the duties and responsibilities provided for in this Agreement. You  represent that you do not possess any confidential, proprietary business information belonging to  any other entity, and will not use any confidential, proprietary business information belonging to  any other entity in connection with your employment with the Company. You represent that you  are not resigning employment or relocating any residence in reliance on any promise or  representation by the Company regarding the kind, character, or existence of such work, or the  length of time such work will last, or the compensation therefor. 
(h) Clawback Policy. The Company may (i) cause the cancellation of any equity or  cash compensation, (ii) require reimbursement of any of your equity or cash compensation and  (iii) effect any other right of recoupment of equity or other compensation provided under this  Agreement or otherwise, in each case to the extent required under applicable law or pursuant to  the requirements of a stock exchange applicable to the Company. In addition, you understand and  agree that incentive compensation paid to you (including, without limitation, bonuses and equity  compensation) shall be subject to recoupment in the event that, subsequent to payment, the Board  reasonably determines that required performance criteria was, in fact, not satisfied (for example,  due to a subsequent financial restatement). 
(i) Violations. You acknowledge that (i) upon a violation of any of the covenants  contained in this Section 8, (ii) if the Company is terminating your employment for Cause as  provided under this Agreement; or (iii)) your breach of the covenants in the Confidentiality  Agreement, the Company would sustain irreparable harm as a result and that the Company would  not have entered into this Agreement without such restrictions, and, therefore, you agree that in  addition to any other remedies which the Company may have, the Company shall be entitled,  without bond of any kind, to seek equitable relief including specific performance and injunctions 
(without posting of bond) restraining you from committing or continuing any such violation.  Moreover, the Company will be entitled to an accounting of profits, compensation, remuneration  or other benefits received by you, in addition to any other contractual, legal or equitable rights,  damages or remedies available. 
9. Entire Agreement. This Agreement and its attachments, the Confidentiality Agreement,  and any other agreements referenced herein, as amended or superseded from time to time, contain  the entire agreement between you and the Company regarding their terms and supersede any and  all prior written or oral understandings other than any award agreements that govern the Pre 

Existing Awards (the “Prior Agreements”). With respect to the Pre-Existing Awards, the  acceleration of vesting provisions contained in this Agreement supersede and replace in their  entirety, and act as amendments to, any acceleration of vesting provisions contained in the award  agreements that govern the Pre-Existing Equity Awards (which agreements, to the extent not  otherwise amended by this Agreement (including, without limitation, under Sections 3 and 4),  remain in full force and effect); provided, however, for purposes of clarity, such provisions do not  supersede or replace Section 16(d) of the 2016 Plan. You agree and acknowledge that you are not  eligible for, and will not receive, any compensation, benefits, vesting acceleration, or severance  pursuant to the Prior Agreements. You also agree and acknowledge that there are no circumstances  as of the date of this Agreement that constitute, and nothing contemplated in this Agreement or  otherwise shall be deemed for any purpose to be or to create, an involuntary termination without  Cause, a Good Reason resignation right, or other “Qualifying Termination” for purposes of the  Prior Agreements or any other severance or change in control plan, agreement or policy maintained  by the Company or its affiliates. Except as otherwise provided herein, this Agreement may not be  amended or modified except in a writing, executed by you and a duly authorized officer of the  Company other than yourself. This Agreement may be executed by facsimile or email signatures  and in counterparts, each of which shall constitute an original, and all of which shall constitute one  and the same instrument. In the event of any conflict between this Agreement and any award  agreements governing the Equity Awards, this Agreement shall prevail. 
10. Choice of Law; Severability; Waiver. This Agreement will be governed by the laws of the  State of California, United States, without reference to the conflict of law provisions thereof. If  any provision of this Agreement, or portion thereof, shall be held invalid or unenforceable by a  court of competent jurisdiction, such invalidity or unenforceability shall attach only to such  provision or portion thereof, and shall not in any manner affect or render invalid or unenforceable  any other provision, or portion thereof, of this Agreement. No breach of any provision hereof can  be waived unless in writing. Waiver of any one breach of any provision hereof will not be deemed  to be a waiver of any other breach of the same or any other provision of this Agreement. 
11. Successors and Assigns. The Company may assign this Agreement to any successor  (whether by amalgamation, merger, consolidation, sale of assets, purchase or otherwise) to all or  substantially all of the equity, assets or business of the Company, and this Agreement will be  binding upon and inure to the benefit of such successors and assigns, including any successor  entity. You may not assign this Agreement or your obligations hereunder. 
12. Notice. Any and all notices required or permitted to be given to you or the Company  pursuant to the provisions of this Agreement will be in writing, and will be effective and deemed  to provide such party sufficient notice hereunder on the earliest of the following: (i) at the time of 
personal delivery, if delivery is in person; (ii) one (1) business day after deposit with an express  overnight courier for United States deliveries, or two (2) business days after such deposit for  deliveries outside of the United States; (iii) three (3) business days after deposit in the United  States mail by certified mail (return receipt requested) for United States deliveries. All notices that  the Company is required to or may desire to give you that are not delivered personally will be sent  with postage and/or other charges prepaid and properly addressed to you at your home address of  record with the Company, or at such other address as you may from time to time designate by one  of the indicated means of notice herein. All notices that you are required to or may desire to give  to the Company that are not delivered personally will be sent with postage and/or other charges  prepaid and properly addressed to the Company’s General Counsel at its principal office, or at  such other office as the Company may from time to time designate by one of the indicated means  of notice herein. 

13. Withholding and Taxes. The Company shall have the right to withhold and deduct from  any payment provided for hereunder or under any other Company plan or agreement any federal,  state, local or foreign taxes of any kind required by law to be withheld with respect to any such  payment. The Company (including without limitation members of the Board) shall not be liable to  you or other persons as to any unexpected or adverse tax consequence realized by you and you  shall be solely responsible for the timely payment of all taxes arising from this Agreement that are  imposed on you. 
14. Section 409A. This Agreement is intended to be exempt from or comply with the  requirements of Code Section 409A (“Section 409A”). In the event this Agreement or any benefit paid to you hereunder is deemed to be subject to Section 409A, you consent to the Company  adopting such conforming amendments as the Company deems necessary, in good faith and in its  reasonable discretion, to comply with Section 409A and avoid the imposition of taxes under  Section 409A. Each payment made pursuant to any provision of this Agreement, including under  Section 4(a), shall be considered a separate payment and not one of a series of payments for  purposes of Section 409A. Notwithstanding anything to the contrary herein, except to the extent  any expense, reimbursement or in-kind benefit provided pursuant to this Agreement does not  constitute a “deferral of compensation” within the meaning of Section 409A: (A) the amount of  expenses eligible for reimbursement or in-kind benefits provided to you during any calendar year  will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to  you in any other calendar year; (B) the reimbursements for expenses for which you are entitled to  be reimbursed shall be made on or before the last day of the calendar year following the calendar  year in which the applicable expense is incurred; and (C) the right to payment or reimbursement  or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit. While it is  intended that all payments and benefits provided under this Agreement to you will be exempt from  or comply with Section 409A, the Company makes no representation or covenant to ensure that  the payments under this Agreement are exempt from or compliant with Section 409A. The  Company will have no liability to you or any other party if a payment or benefit under this  Agreement is challenged by any taxing authority or is ultimately determined not to be exempt or  compliant. You further understand and agree that you will be entirely responsible for any and all  taxes on any benefits payable to you as a result of this Agreement. In addition, if upon your  Separation from Service, you are then a “specified employee” (as defined in Section 409A), then  notwithstanding anything to the contrary in this Agreement, and solely to the extent necessary to  comply with Section 409A and avoid the imposition of taxes under Section 409A, the Company 
shall defer payment of “nonqualified deferred compensation” subject to Section 409A payable as  a result of and within six (6) months following such Separation from Service under this Agreement  until the earlier of (i) the first business day of the seventh month following your Separation from  Service, or (ii) ten (10) days after the Company receives written notification of your death. Any  such delayed payments shall be made without interest. Furthermore, for purposes of compliance  with Section 409A, references to “terminate,” “termination” or the like shall be interpreted to mean  your Separation from Service. Notwithstanding anything to the contrary in this Agreement or the  Release, if you become entitled to vesting acceleration benefits under Section 4(a) with respect to  your RSUs and/or IPO RSUs, and the Release Period spans two calendar years, your unvested  RSUs and IPO RSUs, as applicable, shall not accelerate vesting pursuant to Section 4(a) any earlier  than January 1 in the calendar year immediately following the calendar year in which your  termination occurs. For the avoidance of doubt, termination or forfeiture of any of your Company  equity awards eligible for vesting acceleration under Section 4(a) due to your termination of  employment with the Company shall be tolled to the extent necessary to implement the vesting  acceleration contemplated by Section 4(a), but in no event will your Company stock options remain  outstanding beyond their maximum term to expiration.  

15. Offset. Notwithstanding anything to the contrary in this Agreement, any severance or other  payments or benefits made to you under this Agreement may be reduced, in the Company’s  discretion, by any amounts you owe to the Company or as will be needed to satisfy any future payments you would need to make for continuing post-termination benefits; provided, however,  that any such offsets do not violate Section 409A. 
16. Voluntary Agreement. You acknowledge that you have been advised to review this  Agreement with your own legal counsel and other advisors of your choosing and that prior to  entering into this Agreement, you have had the opportunity to review this Agreement with your  attorney and other advisors and have not asked (or relied upon) the Company or its counsel to  represent you or your counsel in this matter. You further represent that you have carefully read and  understand the scope and effect of the provisions of this Agreement and that you are fully aware  of the legal and binding effect of this Agreement. This Agreement is executed voluntarily by you  and without any duress or undue influence on the part or behalf of the Company. 
17. Definitions. The following definitions shall apply for purposes of this Agreement: 
(a) “Accrued Obligations” shall mean the sum of (i) any portion of your accrued but  unpaid Base Salary through the Termination Date; (ii) subject to Section 14, any compensation  previously earned but deferred by you (together with any interest or earnings thereon) that has not  yet been paid and that is not otherwise to be paid at a later date pursuant to any deferred  compensation arrangement of the Company to which you are a party, if any; (iii) your accrued but  unpaid vacation pay through the Termination Date; (iv) any reimbursements that you are entitled  to receive under Section 6 of the Agreement or otherwise; and (v) any vested benefits or amounts  that you are otherwise entitled to receive under any plan, policy, practice or program of or any  other contract or agreement with the Company in accordance with the terms thereof (other than  any such plan, policy, practice or program of the Company that provides benefits in the nature of  severance or continuation pay). 
(b) “Cause” shall mean that one or more of the following has occurred: 
(i) you have been convicted of, plead guilty or no contest to, or entered into a  plea agreement with respect to (x) any felony (under the laws of the United States, any relevant  state, or the equivalent of a felony in any international jurisdiction in which the Company does  business) or (y) any crime involving dishonesty or moral turpitude; 
(ii) you have engaged in (A) any willful misconduct (including any violation of  federal securities laws) or gross negligence, or (B) any act of dishonesty, violence or threat of  violence, in each case with respect to this clause (B), that would reasonably be expected to result  in a material injury to the Company; 
(iii) you have breached a material written policy of the Company or the rules of  any governmental or regulatory body applicable to the Company; 
(iv) you (y) have willfully failed to materially perform or uphold your duties  under this Agreement and/or (z) willfully fail to comply with lawful directives of the Board  (including, without limitation, failure to comply with business travel requirements set by the  Board); or 
(v) you have materially breached this Agreement or any other material contract  to which you and the Company are parties; 

provided that, with respect to Sections 17(c)(iii), (iv), and (v) and if the event giving rise  to the claim of Cause is curable, the Company provides you written notice of the event within thirty  (30) days of the Company learning of the occurrence of such event, and such Cause event remains  uncured thirty (30) days after the Company has provided such written notice; provided further that  any termination of your employment for “Cause” with respect to Sections 17(c)(iii) or 17(c)(v)  occurs no later than thirty (30) days following the expiration of such cure period.  
(c) “Change in Control” shall mean any one or more of the following: 
(i) any “person” (as such term is used in Section 13(d) and 14(d) of the  Securities Exchange Act of 1934, as amended (the “Exchange Act”)), other than a trustee or other  fiduciary holding securities of the Company under an employee benefit plan of the Company,  becomes the “beneficial owner” (as defined in Rule 13d-3 promulgated under the Exchange Act),  directly or indirectly, of securities of the Company representing fifty percent (50%) or more of (A)  the outstanding shares of common stock of the Company or (B) the combined voting power of the  Company’s then-outstanding securities; 
(ii) the Company is party to a merger or consolidation, or series of related  transactions, which results in the voting securities of the Company outstanding immediately prior  thereto failing to continue to represent (either by remaining outstanding or by being converted into  voting securities of the surviving entity) at least fifty percent (50%) of the combined voting power  of the voting securities of the Company or such surviving entity outstanding immediately after  such merger or consolidation; 
(iii) the sale or disposition of all or substantially all of the Company’s assets (or  consummation of any transaction, or series of related transactions, having similar effect);
(iv) the dissolution or liquidation of the Company; or 
(v) any transaction or series of related transactions that has the substantial effect  of any one or more of the foregoing. 
Notwithstanding the foregoing, to the extent required for compliance with Section 409A,  in no event will a Change in Control be deemed to have occurred if such transaction is not also a  “change in the ownership or effective control of” the Company or “a change in the ownership of a  substantial portion of the assets of” the Company, as determined under Treasury Regulations  Section 1.409A-3(i)(5). In addition, a transfer of ownership or control of the Company between  and among affiliated funds of Francisco Partners shall not be a Change in Control. 
(d) “Change in Control Period” shall mean the period commencing on the Change in  Control and ending 24 months following a Change in Control. 
(e) “Disability” shall mean your medically determinable physical or mental  incapacitation such that for a continuous period of not less than twelve (12) months, you are unable  to engage in any substantial gainful activity or which can be expected to result in death. 
(f) “Good Reason” shall mean any one or more of the following that occur without  your consent: (i) a material diminution in your Base Salary, except for reductions that are  comparable to reductions generally applicable to similarly situated executives of the Company, not  to exceed 10%, (ii) a material diminution in your job title, duties, responsibilities and/or authority  as the Company’s CPO, or (iii) a material change in the geographic location at which you must  perform your services to the Company, which shall be defined to be a relocation of your principal  

workplace to a new location that more than thirty (30) miles away from your then-current principal  workplace. 
(g) “Pre-Existing Awards” shall mean the Time-Based Options, Performance Options  and RSUs. 
(h) “Qualifying Termination” shall mean your employment is terminated without  Cause (excluding by reason of your death or Disability) by the Company or by you for Good  Reason (each, a Qualifying Termination). 
(i) “Separation from Service” has the meaning set forth in Treasury  Regulations Section 1.409A-1(h)(1). 
18. Exhibits. All Exhibits attached to this Agreement shall be incorporated herein by  this reference as though fully set forth herein. 
A duplicate original of this Agreement is enclosed for your records. If you decide to accept  the terms of this Agreement, please sign the enclosed copy of this Agreement in the spaces  indicated and return it to me. Your signature will acknowledge that you have read and understood  and agreed to the terms and conditions of this Agreement. 
[signature page follows]
In witness whereof, the parties have each executed this Agreement as of the dates indicated below.  LegalZoom.com, Inc.  
By:  
Name: Dan Wernikoff  
Its: Chief Executive Officer  

June 16, 2021
Dated:  
 /s/ Rich Preece 
Dated:  June 16, 2021

EXHIBIT A 
FORM OF SEPARATION AGREEMENT AND RELEASE OF ALL CLAIMS AND  COVENANT NOT TO SUE
SEPARATION AGREEMENT AND RELEASE OF ALL CLAIMS AND COVENANT NOT TO SUE 
This Separation Agreement and Release of All Claims and Covenant Not to Sue  (“Release”) is made pursuant to the Employment Agreement (“Employment Agreement”) entered  into by and between Rich Preece (“Employee”) and LegalZoom.com, Inc., a Delaware corporation  (“Company”), to which this Release is an exhibit, in consideration for and as condition precedent  to the Company’s obligation to provide separation benefits to Employee pursuant to the  Employment Agreement and which Employee is otherwise not entitled to receive. Certain terms  if they are not defined in this Release shall have the meaning provided to them in the Employment  Agreement.  
In order for this Release to become effective, Employee must deliver to the Company a  properly signed and dated Release on or after Employee’s Termination Date and before 4:00 pm  PST on [DATE] or else it will be irrevocably determined that Employee has decided to not execute  this Release and this Release shall be null and void with no force or effect. This Release will  become effective only if it has been timely executed by the Employee and the revocation period  has expired without revocation by Employee as set forth in Section 5(a) below (such effective date  of this Release, if any, is the “Effective Date”). By signing below and timely delivering a signed  Release to the Company, Employee acknowledges and agrees to each of the following terms and  conditions: 
1. RECITALS. This Release is made with reference to the following facts: 
Employee and Company are parties to the Employment Agreement which provides that  Employee must execute a general release of all claims and covenant not to sue and deliver it to the  Company in order to be eligible for certain separation benefits from the Company as specified  under the Employment Agreement. This Release is the separation agreement and general release  and covenant not to sue required by the Employment Agreement. If this Release does not become  effective by its own terms, then Employee shall receive none of the separation benefits to be  provided under the Employment Agreement. 
2. QUALIFYING TERMINATION OF EMPLOYMENT. Employee and Company  acknowledge and agree that the Employee’s employment with the Company was terminated [by  the Company without Cause] [by Employee for Good Reason]2(a “Qualifying Termination”) [as  a result of Employee’s Death] [as a result of Employee’s Disability] as of the close of business on  [DATE] (the “Termination Date”), without regard to whether Employee signs this Release or  agrees to the following terms and conditions, and that such termination was treated as a Qualifying  Termination [during the Change in Control Period] [outside of the Change in Control Period]3by the Company. As of the Termination Date, it is mutually agreed that Employee is no longer an  employee of the Company and no longer holds any positions or offices with the Company. 
3. SEPARATION BENEFITS. In consideration for Employee’s general release of all claims  set forth in Section 5 below and Employee’s other obligations under this Release and in satisfaction  of all of the Company’s obligations to Employee and further provided that: (i) this Release is    

2 NTD: To be specified at the time of termination. 
3 NTD: To be specified at the time of termination.
signed by Employee and delivered to the Company on or before [DATE], (ii) this Release is not  revoked by Employee under Section 5 below and therefore becomes effective on or before  [DATE], and (iii) Employee remains in continuing material compliance with all of the terms of  this Release and the Employment Agreement, then the Company agrees to provide (and continue  to provide) the separation benefits specified in Section 4(a) below to Employee. 
In the event that the Company believes Employee is not in continuing material compliance with  the terms of this Release, then the Company shall provide Employee with written notice of the  same and, without limiting its other possible actions, the Company shall immediately terminate  any and all such separation payments and benefits. 
4. PAYMENTS, BENEFITS AND TAXES. 
a. Separation Benefits. The Company will provide to Employee the payments and  benefits specified in [ [Section 4(a)(i)] [Section 4(a)(ii)] [Section 4(a)(iii) ]4of the Employment  Agreement, subject to Section 5 of the Employment Agreement. Subject to Section 4(b) below,  such payments and benefits will be provided to Employee at the times specified in the Employment  Agreement. 
b. Taxes. Any tax obligations of Employee and tax liability therefor, including without  limitation any penalties or interest based upon such tax obligations, that arise from the benefits  and payments made to Employee shall be Employee’s sole responsibility and liability. All  payments or benefits made under this Release to Employee shall be subject to applicable tax  withholding laws and regulations and Employee shall be required to timely and fully satisfy any  such withholding as a condition of receipt of any payments or benefits. The terms of Sections 5,  13 and 14 of the Employment Agreement are also applicable to this Release and to all payments  and benefits provided hereunder. 
c. WARN Payments. The payments to Employee hereunder shall be considered as  including any and all payments by the Company that could or in fact become payable in connection  with the Employee’s termination of employment pursuant to any applicable legal requirements,  including, without limitation, the Worker Adjustment and Retraining Notification Act (the  “WARN” Act), California Labor Code sections 1400-1408, or any other similar foreign, federal  or state law. 
5. EMPLOYEE’S PROMISES. In consideration for the promises and payments contained  in the Employment Agreement, Employee agrees as follows: 
a. Employee hereby covenants not to sue and also waives, releases and forever  discharges the Company and its divisions, subsidiaries, officers, directors, agents, employees,  stockholders, affiliates, attorneys, predecessors and successors from any and all claims, causes of  action, damages or costs of any type and liabilities of whatever kind or nature, in law or in equity,  that Employee has ever had or may have as of the Effective Date (whether known or not known)  (collectively, “Claims”). This waiver and release includes, but is not limited to, claims, causes of  action, damages or costs arising under or in relation to Company’s employee handbook and  personnel policies, or any oral or written representations or statements made by officers, directors,    
4 NTD: To be specified at the time of termination.
employees or agents of Company, and also including but not limited to Claims based on and/or  arising under any state or federal law regulating wages, hours, compensation or employment, or  

any claim for breach of contract or breach of the implied covenant of good faith and fair dealing,  or any claim for wrongful termination, or any discrimination claim on the basis of race, sex, sexual  orientation, gender, age, religion, marital status, national origin, physical or mental disability,  medical condition, or under Title VII of the Civil Rights Act of 1964, as amended, The Americans  with Disabilities Act, The Family Medical Leave Act, The Equal Pay Act, The Employee  Retirement Income Security Act, The Fair Labor Standards Act, The California Fair Employment  and Housing Act, The California Constitution, The California Government Code, The California  Labor Code, The Industrial Welfare Commission’s Orders, The Worker Adjustment and  Retraining Notification Act, the California Labor Code, the California Family Rights Act, Act, the  California Wage Orders, the California Private Attorneys General Act of 2004, the California  Wage Orders, and the California Business and Professions Code Section 17200, et seq., and any  and all other Claims Employee may have under any other federal, state or local Constitution,  Statute, Ordinance and/or Regulation; and all other Claims arising under common law including  but not limited to tort, express and/or implied contract and/or quasi-contract, arising out of or, in  any way, related to Employee’s previous relationship with the Company as an employee,  consultant and/or director. 
Furthermore, Employee expressly acknowledges, understands and agrees that this Release  includes a waiver and release of all claims which Employee has or may have under the Older  Workers Benefit Protection Act and the Age Discrimination in Employment Act of 1967, as  amended, 29 U.S.C. §621, et seq. (“ADEA”). The following terms and conditions apply to and are  part of the waiver and release of ADEA claims under this Release:5 
(1) Employee was advised and encouraged to consult with an attorney before  signing this Release; 
(2) Employee was granted twenty-one (21) days after Employee was presented  with this Release to decide whether or not to sign this Release. Employee understands and agrees  that any modification of this Release, whether material or immaterial, does not restart the running  of this 21-day consideration period; 
(3) Employee will have the right to revoke the waiver and release of claims  under the ADEA within seven (7) days of Employee signing this Release, and this Release shall  not become effective and enforceable until that revocation period has expired without such  revocation; 
(4) Employee hereby acknowledges and agrees that Employee is knowingly  and voluntarily waiving and releasing Employee’s rights and claims, including under the ADEA, in exchange for consideration (something of value) in addition to anything of value to which  Employee is already entitled; and 
(5) Nothing in this Release prevents or precludes Employee from challenging  or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does  
  
5 NTD: ADEA provisions to be updated or removed as applicable.
it impose any condition precedent, penalties or costs from doing so, unless specifically authorized  by federal law. 
Therefore, Employee may unilaterally revoke this Release at any time up to seven (7) calendar  days following Employee’s execution of the Release, and this Release shall not become effective  or enforceable until the revocation period has expired, which is at 12:00:01 a.m. PST on the 

eighth  day following Employee’s execution of this Release. If Employee elects to revoke this Release,  such revocation must be in writing addressed to the General Counsel of the Company and received  by the Company via facsimile or email no later than the end of the seventh day after Employee  signed this Release. 
b. The waiver and release set forth in this Section 5 applies to claims of which  Employee does not currently have knowledge and Employee specifically waives the benefit of the  provisions of Section 1542 of the Civil Code of the State of California which reads as follows: “A  general release does not extend to claims that the creditor or releasing party does not know or  suspect to exist in his or her favor at the time of executing the release and that if known by him or  her, would have materially affected his or her settlement with the debtor or released party.” 
c. Employee agrees that the Company has paid to Employee all salary and vacation  which had accrued as of the Termination Date and that these payments represent all such monies  due to Employee through the Termination Date. In light of the payment by the Company of all  wages due, or to become due to Employee, California Labor Code Section 206.5 is not applicable.  That section provides in pertinent part as follows: “No employer shall require the execution of any  release of any claim or right on account of wages due, or to become due, or made as an advance  on wages to be earned, unless payment of such wages has been made.” Except with respect to any  “Excluded Claims” (specified in Section 5(d) below), Employee further represents and warrants  to the Company that, as of the Effective Date, the payments set forth in Section 4(a) above  constitute all payments or obligations owed by the Company to Employee in connection with any  employment, severance, retention, or a change in control plan or arrangement. 
d. Notwithstanding anything to the contrary, the Employee is not waiving any Claims  Employee may have with respect to any of the following matters: (i) any rights that Employee may  have to file a charge, testify, assist, or cooperate with the U.S. Equal Employment Opportunity  Commission or another fair employment practices governmental agency; (ii) claims for  indemnification from the Company, including without limitation under any contractual  arrangements to which Employee is party with the Company, the Company’s charter and bylaws  and in accordance with Section 2802 of the California Labor Code; (iii) claims to unemployment  compensation benefits or workers compensation benefits; (iv) claims under the Fair Labor  Standards Act; (v) health insurance benefits under the Consolidated Omnibus Budget  Reconciliation Act (COBRA); (vi) claims with regard to vested benefits under a retirement plan  governed by the ERISA; (vii) any events, occurrences, acts or omissions which occur after the  Effective Date; (viii) claims under any directors and officers liability insurance policy or (ix)  claims that may not be released as a matter of applicable law. 
e. Employee has not suffered nor aggravated any known on-the-job injuries for which  Employee has not already filed a Workers’ Compensation claim.
f. Employee agrees that nothing in this Release shall be construed as an admission of  liability of any kind by Company to Employee. 
g. In the event that Employee breaches or threatens to breach any of the provisions  contained in this Section 5, Employee acknowledges that such breach or threatened breach shall  cause irreparable harm, entitling the Company, at its option, to seek immediate injunctive relief,  from a court of competent jurisdiction without waiver of any other rights or remedies from a court  of law or equity and without posting of bond. In addition, should the Company prevail before a  court of competent jurisdiction or arbitration, Employee agrees to reimburse the Company for all  expenses incurred, including reasonable attorneys’ fees. Should Employee attempt to challenge  the enforceability of any provision of this Release, Employee shall initially 

tender to the Company,  by certified check, all amounts received pursuant to this Release and shall not be entitled to receive  any further payment or benefit hereunder or under the Agreements. 
h. Employee reaffirms that Employee will continue to be bound by, and will continue  to comply with, all of the terms and conditions and covenants in Sections 5, 7 through 15 of the  Employment Agreement and also all terms and conditions of the Confidentiality Agreement (as  such term is defined in the Employment Agreement). 
i. Employee represents and warrants to the Company that, as of the Effective Date,  Employee has no outstanding agreement or obligation that is in conflict with any of the provisions  of this Release, or that would preclude Employee from complying with the provisions hereof, and  further certifies that Employee will not enter into any such conflicting agreement. 
j. Employee will not, at any time following the Termination Date, make (or direct  anyone else to make) any disparaging statements (oral or written) about the Company, or any of  its affiliated entities, officers, directors, employees, stockholders, representatives or agents, or any  of the Company’s products or services or work-in-progress, that are harmful to their businesses,  business reputations or personal reputations. The Company will not in any authorized corporate  communication, and will instruct the members of the Board to not, make (or direct anyone else to  make) any disparaging statements (oral or written) about the Employee, that are harmful to the  Employee’s businesses, business reputation or personal reputation. Notwithstanding this Section  5(j), nothing herein shall prohibit any party from providing truthful testimony in connection with  a governmental investigation or legal proceeding or from reporting a suspected violation of law. 
6. MISCELLANEOUS. 
a. This Release shall be deemed to have been executed and delivered within the State  of California, and the rights and obligations of the Company and Employee shall be construed and  enforced in accordance with, and governed by, the laws of the State of California. 
b. This Release, and the surviving provisions of the Employment Agreement, are the  entire agreement with respect to the subject matter hereof and supersedes all prior and  contemporaneous oral and written agreements and discussions. This Release may be amended only  by an agreement in a writing signed by Employee and an authorized representative of the Company  and which expressly references that this Release is being amended. Employees agree that the 
release set forth in Section 5 above shall be and remain in effect in all respects as a complete  general release as to the matters released. 
c. This Release is binding upon and shall inure to the benefit of the Company, its  respective agents, employees, representatives, officers, directors, divisions, subsidiaries, affiliates,  any parent company, assigns, heirs, partners, successors in interest and stockholders, including any  successor company of the Company. 
d. Employee agrees that Employee has read this Release and has had the opportunity  to ask questions, seek counsel and time to consider the terms of the Release. Employee has entered  into this Release freely and voluntarily. 
e. Employee understands and agrees that Employee is solely responsible for any and  all liability under federal and state tax laws arising from the payments made under the Agreements.  

Employee understands that the released parties make no warranty concerning the treatment of any  funds paid hereunder under said laws, and Employee has not relied upon any such warranties. 
f. Employee declares, covenants and agrees that Employee has not assigned  heretofore, and has not and will not hereafter sue, any of the released parties before any court or  governmental agency, commission, division or department, whether state, federal or local, upon  any claim, demand or cause of action released herein. 
g. If any provision of this Release or application thereof is held invalid, the invalidity  shall not affect other provisions or applications of the Release which can be given effect without  the invalid provision or application. To this end, the provisions of this Release are severable. 
Rich Preece (“Employee”) 
Date:  
LegalZoom.com, Inc. 
By:  
Its:  
Dated: 
EXHIBIT B 
CONFIDENTIAL INFORMATION AND EMPLOYEE INVENTION ASSIGNMENT  AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]